Rare Disease Trial Updates: August 2026

In August 2026, Trial Friend tracked 986 rare disease clinical trial updates across 117 conditions, including 12 FDA-related actions and 172 trial status changes, alongside enrollment updates and new trial site openings sourced from ClinicalTrials.gov and FDA announcements.

This is a permanent monthly archive. For the latest updates, see the live current events feed.

Major Updates: FDA Actions, Status Changes & Results

Status ChangeRett SyndromeAug 31Rett Syndrome Research TrustNCT06338267
No longer enrolling new participants

No longer enrolling new participants

company_8kAug 31
BridgeBio Pharma disclosed a material event (company event)

BridgeBio Pharma (BBIO) filed an 8-K with the SEC on 2026-08-31 covering: company event. Companies must file 8-Ks for material events within 4 business days, and clinical, regulatory, and business news sometimes appears here before any press release.

company_8kAchondroplasiaAug 31
BioMarin Pharmaceutical disclosed a material event involving Achondroplasia (material agreement)

BioMarin Pharmaceutical (BMRN) filed an 8-K with the SEC on 2026-08-31 covering: material agreement. The filing mentions Achondroplasia. Companies must file 8-Ks for material events within 4 business days, and clinical, regulatory, and business news sometimes appears here before any press release.

company_8kAug 31
Jazz Pharmaceuticals disclosed a material event (material agreement, company event)

Jazz Pharmaceuticals (JAZZ) filed an 8-K with the SEC on 2026-08-31 covering: material agreement, company event. Companies must file 8-Ks for material events within 4 business days, and clinical, regulatory, and business news sometimes appears here before any press release.

company_8kHeparin-Induced ThrombocytopeniaAug 31
Cadrenal Therapeutics: CURRENT REPORT.

Cadrenal Therapeutics (CVKD) filed an 8-K with the SEC on 2026-08-31 covering: company event. The filing mentions Heparin-Induced Thrombocytopenia. Companies must file 8-Ks for material events within 4 business days, and clinical, regulatory, and business news sometimes appears here before any press release.

Status ChangePulmonary Arterial HypertensionAug 31PfizerNCT07073820
No longer enrolling new participants

No longer enrolling new participants

Status ChangePrimary Biliary CholangitisAug 31Umecrine Cognition ABNCT07304843
No longer enrolling new participants

No longer enrolling new participants

Status ChangePrimary Biliary CholangitisAug 31Mirum Pharmaceuticals, Inc.NCT05050136
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMyelofibrosisAug 30Geron CorporationNCT05371964
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMultiple System AtrophyAug 30Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaNCT06846658
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMesotheliomaAug 30M.D. Anderson Cancer CenterNCT03007030
No longer enrolling new participants

No longer enrolling new participants

Status ChangeLimb-Girdle Muscular DystrophyAug 29AskBio IncNCT05230459
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHuntington DiseaseAug 29Hoffmann-La RocheNCT07246941
Now recruiting (was Active Not Recruiting)

Now recruiting (was Active Not Recruiting)

Status ChangeHodgkin LymphomaAug 29Barbara Ann Karmanos Cancer InstituteNCT00935090
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHodgkin LymphomaAug 29Fondazione Italiana Linfomi - ETSNCT05249959
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHodgkin LymphomaAug 29AbbVieNCT05512390
No longer enrolling new participants

No longer enrolling new participants

FDA ApprovalPolycythemia VeraAug 28
FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorder

The U.S. Food and Drug Administration today approved Mimrylo (rusfertide), a new treatment for adults with polycythemia vera, a rare blood disorder that causes the body to make too many red blood cells.

FDA ApprovalDermatomyositisAug 27
FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults

The U.S. Food and Drug Administration has approved Lisraya (brepocitinib) tablets for the treatment of dermatomyositis in adults.

Status ChangeChronic Graft-versus-Host DiseaseAug 27Terry L. WahlsNCT05057676
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseAug 27M.D. Anderson Cancer CenterNCT03128879
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseAug 27Ohio State UniversityNCT05753345
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseAug 27Alleviant Medical, Inc.NCT05685303
Now recruiting (was Enrolling By Invitation)

Now recruiting (was Enrolling By Invitation)

Status ChangeChronic Graft-versus-Host DiseaseAug 27Vastra Gotaland RegionNCT04561986
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseAug 27Hoffmann-La RocheNCT07667322
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseAug 27Radboud University Medical CenterNCT02383342
No longer enrolling new participants

No longer enrolling new participants

FDA NewsAug 27
FDA Issues Emergency Use Authorization for Generic Drug to Prevent New World Screwworm in Cattle

FDA issues Emergency Use Authorization (EUA) for Bimectin (ivermectin) injection for the prevention of New World screwworm (NWS) infestations (myiasis) in cattle when administered within 24 hours of birth, at the time of castration, or at the appearance of a wound.

Status ChangeCystic FibrosisAug 27Massachusetts General HospitalNCT06810167
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Granulomatous DiseaseAug 27EnsomaNCT06876363
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseAug 27Manchester University NHS Foundation TrustNCT05653193
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseAug 27Northwestern UniversityNCT05703178
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseAug 27Chinese University of Hong KongNCT06715735
Now recruiting (was Active Not Recruiting)

Now recruiting (was Active Not Recruiting)

Status ChangeChronic Graft-versus-Host DiseaseAug 27National Taiwan University HospitalNCT06161038
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseAug 27Duke-NUS Graduate Medical SchoolNCT05295368
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseAug 27BayerNCT05196035
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseAug 27Albert Einstein College of MedicineNCT05492825
No longer enrolling new participants

No longer enrolling new participants

Status ChangeCholangiocarcinomaAug 27iOMEDICO AGNCT04510740
No longer enrolling new participants

No longer enrolling new participants

FDA ApprovalAug 26
FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer

The U.S. Food and Drug Administration today approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule.

Status ChangeAngelman SyndromeAug 26Ionis Pharmaceuticals, Inc.NCT05127226
No longer enrolling new participants

No longer enrolling new participants

FDA NewsAug 25
FDA Authorizes First Wearable Device That Continuously Monitors Both Ketone Levels and Blood Sugar

The U.S. Food and Drug Administration today authorized the Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for people aged 2 years and older living with diabetes.

Status ChangeSickle Cell DiseaseAug 25Washington University School of MedicineNCT04406818
No longer enrolling new participants

No longer enrolling new participants

Status ChangeShort Bowel SyndromeAug 24Jessica SosioNCT06326645
No longer enrolling new participants

No longer enrolling new participants

Status ChangeSevere Combined ImmunodeficiencyAug 24University of California, Los AngelesNCT05432310
No longer enrolling new participants

No longer enrolling new participants

Status ChangeSarcoidosisAug 24Xentria, Inc.NCT06169397
No longer enrolling new participants

No longer enrolling new participants

Status ChangeRett SyndromeAug 24Taysha Gene Therapies, Inc.NCT07480564
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMyotonic DystrophyAug 23Vertex Pharmaceuticals IncorporatedNCT06185764
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMyelodysplastic SyndromesAug 23Franziska WachterNCT05796570
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMyelodysplastic SyndromesAug 23Swedish Orphan BiovitrumNCT06782373
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMultiple System AtrophyAug 23Vertex Pharmaceuticals IncorporatedNCT06185764
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMultiple System AtrophyAug 23Dasher Neuroscience Inc.NCT06848231
No longer enrolling new participants

No longer enrolling new participants

Status ChangeIdiopathic Pulmonary FibrosisAug 22University of California, Los AngelesNCT05365802
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHypersensitivity PneumonitisAug 22University of California, Los AngelesNCT05365802
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHodgkin LymphomaAug 22Cho Pharma Inc.NCT05950165
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHodgkin LymphomaAug 22Janssen Research & Development, LLCNCT05421663
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHodgkin LymphomaAug 22University of WashingtonNCT04231877
No longer enrolling new participants

No longer enrolling new participants

Status ChangeGeographic AtrophyAug 21Perceive Biotherapeutics, Inc.NCT06087458
No longer enrolling new participants

No longer enrolling new participants

Status ChangeGaucher DiseaseAug 21Prevail TherapeuticsNCT05487599
No longer enrolling new participants

No longer enrolling new participants

Status ChangeFabry DiseaseAug 21Sangamo TherapeuticsNCT05039866
No longer enrolling new participants

No longer enrolling new participants

Status ChangeInherited ErythromelalgiaAug 21St. Olavs HospitalNCT04039633
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseAug 20Michael HoelscherNCT06513286
Now recruiting (was Enrolling By Invitation)

Now recruiting (was Enrolling By Invitation)

Status ChangeChronic Graft-versus-Host DiseaseAug 20University of ConnecticutNCT06579027
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseAug 20University of BrasiliaNCT06651099
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseAug 20Dana-Farber Cancer InstituteNCT06736548
Status changed from Recruiting to Enrolling By Invitation

Status changed from Recruiting to Enrolling By Invitation

Status ChangeCystic FibrosisAug 20ReCode TherapeuticsNCT06237335
No longer enrolling new participants

No longer enrolling new participants

Status ChangeCushing DiseaseAug 20Crinetics Pharmaceuticals Inc.NCT05804669
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseAug 20Boston University Charles River CampusNCT06493903
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseAug 20University of British ColumbiaNCT03674307
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseAug 20Zura Bio IncNCT06993610
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseAug 20Mayo ClinicNCT05755945
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseAug 20Hoffmann-La RocheNCT05878769
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseAug 20University of California, San FranciscoNCT06152653
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseAug 20University of NottinghamNCT06518278
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseAug 20Eli Lilly and CompanyNCT07035093
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseAug 20Region Örebro CountyNCT07092332
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseAug 20AbbVieNCT02966756
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseAug 20St. Olavs HospitalNCT05372822
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseAug 20Alexion Pharmaceuticals, Inc.NCT06291376
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseAug 20University of Kansas Medical CenterNCT06804551
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseAug 20Weill Medical College of Cornell UniversityNCT04542161
No longer enrolling new participants

No longer enrolling new participants

FDA ApprovalAug 19
FDA Approves First Therapy for Patients aged 8 years and older with Glycogen Storage Disease Type Ia

The U.S. Food and Drug Administration today issued an accelerated approval for Genglycos (pariglasgene brecaparvovec-opnr) as the first-ever treatment for adults and children 8 years of age and older with glycogen storage disease type Ia (GSDIa)

FDA NewsAug 19
FDA Authorizes First-Of-Its-Kind Robotic Blood Draw Device

The U.S. Food and Drug Administration today authorized the Aletta, the first standalone robotic device that can draw blood from a patient’s arm without hands-on operator intervention.

Status ChangeATTR Amyloidosis (Transthyretin Amyloidosis)Aug 19Yale UniversityNCT07398950
Status changed from Recruiting to Enrolling By Invitation

Status changed from Recruiting to Enrolling By Invitation

Status ChangeAmyotrophic Lateral SclerosisAug 19BiogenNCT07223723
No longer enrolling new participants

No longer enrolling new participants

FDA NewsAug 18
FDA Seeks Public Feedback to Inform Regulatory Approach for Generative AI-Enabled Medical Devices

The U.S. Food and Drug Administration today issued a discussion paper on considerations for the regulation of generative artificial intelligence (GenAI)-enabled medical devices, seeking feedback from interested parties on risk assessment, premarket evaluation, postmarket monitoring, and other topics

Status ChangeSickle Cell DiseaseAug 18University of CincinnatiNCT06725550
Now recruiting (was Active Not Recruiting)

Now recruiting (was Active Not Recruiting)

Status ChangeSickle Cell DiseaseAug 18Children's Hospital Medical Center, CincinnatiNCT03948867
No longer enrolling new participants

No longer enrolling new participants

Status ChangePulmonary Arterial HypertensionAug 17Gustavo A Heresi, MD, MSNCT06992440
Now recruiting (was Enrolling By Invitation)

Now recruiting (was Enrolling By Invitation)

Status ChangePolycythemia VeraAug 17Barbara Ann Karmanos Cancer InstituteNCT00935090
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMyelofibrosisAug 16Chengdu Zenitar Biomedical Technology Co., LtdNCT06457425
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMyelofibrosisAug 16Incyte CorporationNCT05936359
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMyelofibrosisAug 16Barbara Ann Karmanos Cancer InstituteNCT00935090
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMyelofibrosisAug 16Incyte CorporationNCT06313593
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMyelodysplastic SyndromesAug 16Barbara Ann Karmanos Cancer InstituteNCT00935090
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMyasthenia GravisAug 16Cabaletta BioNCT06359041
Now recruiting (was Active Not Recruiting)

Now recruiting (was Active Not Recruiting)

Status ChangeMyasthenia GravisAug 16Novartis PharmaceuticalsNCT06517758
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMultiple SclerosisAug 16Terry L. WahlsNCT05057676
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMultiple SclerosisAug 16Hoffmann-La RocheNCT07667322
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMembranous NephropathyAug 16Shoichi Maruyama MD PhDNCT05914155
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMastocytosisAug 16Barbara Ann Karmanos Cancer InstituteNCT00935090
No longer enrolling new participants

No longer enrolling new participants

Status ChangeLimb-Girdle Muscular DystrophyAug 15Rigshospitalet, DenmarkNCT05102799
No longer enrolling new participants

No longer enrolling new participants

Status ChangeLight Chain AmyloidosisAug 15Barbara Ann Karmanos Cancer InstituteNCT00935090
No longer enrolling new participants

No longer enrolling new participants

Status ChangeIgA NephropathyAug 15Hoffmann-La RocheNCT05797610
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHypoparathyroidismAug 15Amorphical Ltd.NCT06547151
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHomozygous Familial HypercholesterolemiaAug 15Arrowhead PharmaceuticalsNCT07037771
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHomocystinuriaAug 15Travere Therapeutics, Inc.NCT03406611
Now recruiting (was Active Not Recruiting)

Now recruiting (was Active Not Recruiting)

Status ChangeHodgkin LymphomaAug 15University of RochesterNCT03739502
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHodgkin LymphomaAug 15BeOne MedicinesNCT05100862
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHodgkin LymphomaAug 15Divaya BhutaniNCT05346809
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHodgkin LymphomaAug 15University of BolognaNCT05725720
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHodgkin LymphomaAug 15University of BirminghamNCT03899337
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHodgkin LymphomaAug 15AbbVieNCT06667687
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHodgkin LymphomaAug 15Hoffmann-La RocheNCT05169515
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHemophilia AAug 14Jiangsu BioJeTay Biotechnology Co., Ltd.NCT06922045
No longer enrolling new participants

No longer enrolling new participants

Status ChangeGraves’ DiseaseAug 14AmgenNCT06401044
No longer enrolling new participants

No longer enrolling new participants

Status ChangeEssential ThrombocythemiaAug 14Barbara Ann Karmanos Cancer InstituteNCT00935090
No longer enrolling new participants

No longer enrolling new participants

Status ChangeEssential ThrombocythemiaAug 14Incyte CorporationNCT05936359
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseAug 13Brigham and Women's HospitalNCT06190158
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseAug 13Stony Brook UniversityNCT04422652
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseAug 13Icahn School of Medicine at Mount SinaiNCT06585254
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseAug 13Uniquity One (UNI)NCT06496620
No longer enrolling new participants

No longer enrolling new participants

Status ChangeCholangiocarcinomaAug 13Apollo Therapeutics LtdNCT06399757
No longer enrolling new participants

No longer enrolling new participants

FDA NewsAug 13
FDA Issues Emergency Use Authorization for Drug to Treat New World Screwworm in Dogs and Puppies

The U.S. Food and Drug Administration today issued an Emergency Use Authorization (EUA) for Simparica TRIO (sarolaner, moxidectin, and pyrantel chewable tablets) for the treatment of New World screwworm (NWS) infestations (myiasis) in dogs and puppies.

Status ChangeEosinophilic EsophagitisAug 13Regeneron PharmaceuticalsNCT06693531
No longer enrolling new participants

No longer enrolling new participants

Status ChangeDermatomyositisAug 13National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)NCT00059748
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Inflammatory Demyelinating PolyneuropathyAug 13SanofiNCT06290128
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseAug 13SanofiNCT07424144
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseAug 13Andreas StallmachNCT03843385
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseAug 13Abbott Medical DevicesNCT07287423
Now recruiting (was Active Not Recruiting)

Now recruiting (was Active Not Recruiting)

Status ChangeChronic Graft-versus-Host DiseaseAug 13M.D. Anderson Cancer CenterNCT05007873
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseAug 13National Cancer Institute (NCI)NCT04044365
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseAug 13University of BirminghamNCT03899337
No longer enrolling new participants

No longer enrolling new participants

Status ChangeATTR Amyloidosis (Transthyretin Amyloidosis)Aug 12AstraZenecaNCT07338942
No longer enrolling new participants

No longer enrolling new participants

Status ChangeWaldenström MacroglobulinemiaAug 11Barbara Ann Karmanos Cancer InstituteNCT00935090
No longer enrolling new participants

No longer enrolling new participants

Status ChangeWaldenström MacroglobulinemiaAug 11BeiGeneNCT07169331
No longer enrolling new participants

No longer enrolling new participants

Status ChangeSystemic MastocytosisAug 11Barbara Ann Karmanos Cancer InstituteNCT00935090
No longer enrolling new participants

No longer enrolling new participants

Status ChangePulmonary Arterial HypertensionAug 10Sheffield Teaching Hospitals NHS Foundation TrustNCT05825417
No longer enrolling new participants

No longer enrolling new participants

Status ChangePhenylketonuriaAug 10The First Affiliated Hospital of Bengbu Medical UniversityNCT06061614
No longer enrolling new participants

No longer enrolling new participants

Status ChangeNeuromyelitis OpticaAug 9Tianjin Medical University General HospitalNCT05792462
No longer enrolling new participants

No longer enrolling new participants

Status ChangeNeurofibromatosis Type 1Aug 9David MillerNCT06515860
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMyelodysplastic SyndromesAug 9M.D. Anderson Cancer CenterNCT02392572
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMyasthenia GravisAug 9Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyNCT06220201
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMultiple SclerosisAug 9Hoffmann-La RocheNCT07074886
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMultiple SclerosisAug 9ABLE Human Motion S.L.NCT07550699
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMultiple SclerosisAug 9Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyNCT06220201
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMedullary Thyroid CancerAug 9M.D. Anderson Cancer CenterNCT06444880
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMedullary Thyroid CancerAug 9Gustave Roussy, Cancer Campus, Grand ParisNCT07016230
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHuntington DiseaseAug 8Hoffmann-La RocheNCT07246941
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHodgkin LymphomaAug 8National Cancer Institute (NCI)NCT03922724
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHodgkin LymphomaAug 8MacroGenicsNCT05362773
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHodgkin LymphomaAug 8ADC Therapeutics S.A.NCT04970901
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHodgkin LymphomaAug 8Hoffmann-La RocheNCT05954910
Now recruiting (was Active Not Recruiting)

Now recruiting (was Active Not Recruiting)

FDA NewsAug 7
FDA Issues Emergency Use Authorization for Drug to Prevent New World Screwworm in Multiple Species, Including Sheep, Cattle, Goats, and Swine

FDA today issued an Emergency Use Authorization (EUA) for CLiK Extra (dicyclanil topical suspension) wound spray for application on or around wounds for the prevention of New World screwworm (NWS) infestations (myiasis).

Status ChangeFocal EpilepsyAug 7Praxis Precision MedicinesNCT07505004
No longer enrolling new participants

No longer enrolling new participants

FDA ApprovalAug 6
FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma

The U.S. Food and Drug Administration today granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg), a genetically modified oncolytic viral therapy for the treatment of advanced, refractory melanoma.

Status ChangeChronic Graft-versus-Host DiseaseAug 6Vanderbilt University Medical CenterNCT06027255
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseAug 6University of Southern CaliforniaNCT04734847
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseAug 6Cedars-Sinai Medical CenterNCT05664880
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseAug 6Karolinska InstitutetNCT05877534
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseAug 6Hoffmann-La RocheNCT07483450
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseAug 6The University of Texas at ArlingtonNCT03982160
No longer enrolling new participants

No longer enrolling new participants

Status ChangeCystic FibrosisAug 6University of Alabama at BirminghamNCT07102043
Status changed from Recruiting to Enrolling By Invitation

Status changed from Recruiting to Enrolling By Invitation

Status ChangeChronic Graft-versus-Host DiseaseAug 6Ossium Health, Inc.NCT05589896
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseAug 6Imam Abdulrahman Bin Faisal UniversityNCT07607314
No longer enrolling new participants

No longer enrolling new participants

Status ChangeChronic Graft-versus-Host DiseaseAug 6Saint Francis HospitalNCT06246526
Now recruiting (was Active Not Recruiting)

Now recruiting (was Active Not Recruiting)

Status ChangeChronic Graft-versus-Host DiseaseAug 6University of CalgaryNCT04561401
No longer enrolling new participants

No longer enrolling new participants

Status ChangeCholangiocarcinomaAug 6Servier Affaires MédicalesNCT05876754
No longer enrolling new participants

No longer enrolling new participants

Status ChangeCholangiocarcinomaAug 6Tyra Biosciences, IncNCT06160752
No longer enrolling new participants

No longer enrolling new participants

FDA ApprovalNarcolepsy Type 1Aug 5
FDA Approves First Drug to Treat the Full Range of Narcolepsy Type 1 Symptoms

The FDA approved Orzeyful (oveporexton) tablets for the treatment of narcolepsy type 1 in adults.

Status ChangeATTR Amyloidosis (Transthyretin Amyloidosis)Aug 5Intellia TherapeuticsNCT05697861
Status changed from Recruiting to Enrolling By Invitation

Status changed from Recruiting to Enrolling By Invitation

Status ChangeWild-Type ATTR Cardiac AmyloidosisAug 4Intellia TherapeuticsNCT05697861
Status changed from Recruiting to Enrolling By Invitation

Status changed from Recruiting to Enrolling By Invitation

Status ChangeWaldenström MacroglobulinemiaAug 4AbbVieNCT07387471
No longer enrolling new participants

No longer enrolling new participants

Status ChangeSickle Cell DiseaseAug 4City of Hope Medical CenterNCT05384756
No longer enrolling new participants

No longer enrolling new participants

Status ChangeSickle Cell DiseaseAug 4University of CincinnatiNCT06725550
No longer enrolling new participants

No longer enrolling new participants

Status ChangeShort Bowel SyndromeAug 3Zealand PharmaNCT07228403
No longer enrolling new participants

No longer enrolling new participants

Status ChangeRetinitis PigmentosaAug 3jCyte, IncNCT06912633
No longer enrolling new participants

No longer enrolling new participants

Status ChangePulmonary Arterial HypertensionAug 3Gossamer Bio USA, Inc.NCT06274801
Now recruiting (was Active Not Recruiting)

Now recruiting (was Active Not Recruiting)

Status ChangePrimary Biliary CholangitisAug 3Xijing Hospital of Digestive DiseasesNCT07104201
No longer enrolling new participants

No longer enrolling new participants

Status ChangePolycythemia VeraAug 3Disc Medicine, IncNCT06985147
No longer enrolling new participants

No longer enrolling new participants

Status ChangePolycystic Kidney DiseaseAug 3Vertex Pharmaceuticals IncorporatedNCT07161037
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMyotonic DystrophyAug 2Hanns LochmullerNCT06809049
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMyelodysplastic SyndromesAug 2MacroGenicsNCT05362773
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMedullary Thyroid CancerAug 2University of Southern CaliforniaNCT07259304
No longer enrolling new participants

No longer enrolling new participants

Status ChangeMastocytosisAug 2MacroGenicsNCT05362773
No longer enrolling new participants

No longer enrolling new participants

Status ChangeLight Chain AmyloidosisAug 1Peking Union Medical College HospitalNCT06629818
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHodgkin LymphomaAug 1AbbVieNCT07387471
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHodgkin LymphomaAug 1MeiraGTx, LLCNCT05926765
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHodgkin LymphomaAug 1Ossium Health, Inc.NCT05589896
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHodgkin LymphomaAug 1University of Southern CaliforniaNCT07259304
No longer enrolling new participants

No longer enrolling new participants

Status ChangeHodgkin LymphomaAug 1Children's Oncology GroupNCT02981628
No longer enrolling new participants

No longer enrolling new participants

Trial Site & Enrollment Activity

sites_addedPulmonary Arterial HypertensionAug 31Merck Sharp & Dohme LLCNCT07218029
Added 1 new site: Hamilton, Canada

Added 1 new site: Hamilton, Canada

sites_addedProgressive Familial Intrahepatic CholestasisAug 31IpsenNCT07185919
Added 1 new site: Seoul, South Korea

Added 1 new site: Seoul, South Korea

sites_addedProgressive Familial Intrahepatic CholestasisAug 31IpsenNCT07588880
Added 1 new site: Chongqing, China

Added 1 new site: Chongqing, China

sites_addedPrimary Sclerosing CholangitisAug 31IpsenNCT07387549
Added 7 new sites: Coronado, California, Englewood, Colorado, Littleton, Colorado and 4 more

Added 7 new sites: Coronado, California, Englewood, Colorado, Littleton, Colorado and 4 more

sites_addedPrimary Biliary CholangitisAug 31IpsenNCT07387549
Added 7 new sites: Coronado, California, Englewood, Colorado, Littleton, Colorado and 4 more

Added 7 new sites: Coronado, California, Englewood, Colorado, Littleton, Colorado and 4 more

sites_addedPolycythemia VeraAug 31Novartis PharmaceuticalsNCT07357727
Added 3 new sites: Jupiter, Florida, Houston, Texas, Kocaeli, Turkey (Türkiye)

Added 3 new sites: Jupiter, Florida, Houston, Texas, Kocaeli, Turkey (Türkiye)

sites_addedPulmonary Arterial HypertensionAug 31United TherapeuticsNCT06388421
Added 4 new sites: Sacramento, California, Columbus, Georgia, Troy, Michigan and 1 more

Added 4 new sites: Sacramento, California, Columbus, Georgia, Troy, Michigan and 1 more

sites_removedPulmonary Arterial HypertensionAug 31PfizerNCT07073820
Reduced from 48 to 27 sites

Reduced from 48 to 27 sites

sites_removedPrimary Biliary CholangitisAug 31Umecrine Cognition ABNCT07304843
Reduced from 40 to 38 sites

Reduced from 40 to 38 sites

Enrollment UpdatePrimary Biliary CholangitisAug 31Mirum Pharmaceuticals, Inc.NCT05050136
Target enrollment increased from 260 to 333

Target enrollment increased from 260 to 333

sites_addedPrader-Willi SyndromeAug 31Harmony Biosciences Management, Inc.NCT06366464
Added 3 new sites: Baltimore, Maryland, Morrisville, North Carolina, Florence, Italy

Added 3 new sites: Baltimore, Maryland, Morrisville, North Carolina, Florence, Italy

sites_addedPolycythemia VeraAug 31Novartis PharmaceuticalsNCT07357727
Added 4 new sites: Tainan, Taiwan, Ankara, Turkey (Türkiye), Ankara, Turkey (Türkiye) and 1 more

Added 4 new sites: Tainan, Taiwan, Ankara, Turkey (Türkiye), Ankara, Turkey (Türkiye) and 1 more

sites_addedPolycystic Kidney DiseaseAug 31University Medical Center GroningenNCT05373264
Added 3 new sites: Graz, Austria, Innsbruck, Austria, Leipzig, Germany

Added 3 new sites: Graz, Austria, Innsbruck, Austria, Leipzig, Germany

sites_addedPheochromocytomaAug 31Children's Oncology GroupNCT02402244
Added 4 new sites: Peoria, Illinois, Norton Shores, Michigan, Tulsa, Oklahoma and 1 more

Added 4 new sites: Peoria, Illinois, Norton Shores, Michigan, Tulsa, Oklahoma and 1 more

sites_addedPhelan-McDermid SyndromeAug 31Neuren Pharmaceuticals LimitedNCT07281079
Added 1 new site: Charlottesville, Virginia

Added 1 new site: Charlottesville, Virginia

sites_addedParagangliomaAug 31Children's Oncology GroupNCT02402244
Added 4 new sites: Peoria, Illinois, Norton Shores, Michigan, Tulsa, Oklahoma and 1 more

Added 4 new sites: Peoria, Illinois, Norton Shores, Michigan, Tulsa, Oklahoma and 1 more

sites_removedNTRK Fusion CancerAug 31Hoffmann-La RocheNCT02568267
Reduced from 130 to 120 sites

Reduced from 130 to 120 sites

sites_addedNoonan SyndromeAug 30BioMarin PharmaceuticalNCT06668805
Added 5 new sites: Milwaukee, Wisconsin, Toronto, Canada, Montreal, Canada and 2 more

Added 5 new sites: Milwaukee, Wisconsin, Toronto, Canada, Montreal, Canada and 2 more

eligibility_changeNoonan SyndromeAug 30BioMarin PharmaceuticalNCT06668805
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMyotonic DystrophyAug 30Avidity Biosciences, Inc.NCT07587242
Added 1 new site: Liège, Belgium

Added 1 new site: Liège, Belgium

sites_addedMyelofibrosisAug 30CERo Therapeutics Holdings, Inc.NCT06834282
Added 1 new site: Seattle, Washington

Added 1 new site: Seattle, Washington

sites_addedMyelofibrosisAug 30Novartis PharmaceuticalsNCT07357727
Added 4 new sites: Tainan, Taiwan, Ankara, Turkey (Türkiye), Ankara, Turkey (Türkiye) and 1 more

Added 4 new sites: Tainan, Taiwan, Ankara, Turkey (Türkiye), Ankara, Turkey (Türkiye) and 1 more

sites_addedMyelofibrosisAug 30TakedaNCT07623161
Added 2 new sites: Gilbert, Arizona, Durham, North Carolina

Added 2 new sites: Gilbert, Arizona, Durham, North Carolina

sites_removedMyelofibrosisAug 30Geron CorporationNCT05371964
Reduced from 8 to 6 sites

Reduced from 8 to 6 sites

sites_addedMyelodysplastic SyndromesAug 30CERo Therapeutics Holdings, Inc.NCT06834282
Added 1 new site: Seattle, Washington

Added 1 new site: Seattle, Washington

eligibility_changeMyelodysplastic SyndromesAug 30Uma BorateNCT06523556
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMyelodysplastic SyndromesAug 30National Cancer Institute (NCI)NCT05554406
Added 1 new site: Ottawa, Canada

Added 1 new site: Ottawa, Canada

sites_addedMyelodysplastic SyndromesAug 30PedAL BCU, LLCNCT04726241
Added 3 new sites: Peoria, Illinois, Houston, Texas, San Juan, Puerto Rico

Added 3 new sites: Peoria, Illinois, Houston, Texas, San Juan, Puerto Rico

sites_addedMyelodysplastic SyndromesAug 30Janssen Research & Development, LLCNCT06788509
Added 2 new sites: Copenhagen, Denmark, Odense C, Denmark

Added 2 new sites: Copenhagen, Denmark, Odense C, Denmark

sites_addedMyasthenia GravisAug 30Dianthus TherapeuticsNCT07647510
Added 2 new sites: Boca Raton, Florida, Houston, Texas

Added 2 new sites: Boca Raton, Florida, Houston, Texas

sites_addedMyasthenia GravisAug 30Miriam FreimerNCT07215949
Added 2 new sites: Tampa, Florida, Kansas City, Kansas

Added 2 new sites: Tampa, Florida, Kansas City, Kansas

sites_addedMyasthenia GravisAug 30UCB Biopharma SRLNCT07463521
Added 5 new sites: Scottsdale, Arizona, O'Fallon, Illinois, Greenfield, Wisconsin and 2 more

Added 5 new sites: Scottsdale, Arizona, O'Fallon, Illinois, Greenfield, Wisconsin and 2 more

sites_addedMultiple SclerosisAug 30Novartis PharmaceuticalsNCT06846281
Added 1 new site: Joinville, Brazil

Added 1 new site: Joinville, Brazil

eligibility_changeMultiple SclerosisAug 30Novartis PharmaceuticalsNCT06846281
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMultiple SclerosisAug 30Zenas BioPharma (USA), LLCNCT07299019
Added 3 new sites: Cordova, Tennessee, Tallinn, Estonia, Poznan, Poland

Added 3 new sites: Cordova, Tennessee, Tallinn, Estonia, Poznan, Poland

sites_addedMultiple SclerosisAug 30Reunion Neuroscience IncNCT07002034
Added 2 new sites: Chicago, Illinois, Worcester, Massachusetts

Added 2 new sites: Chicago, Illinois, Worcester, Massachusetts

eligibility_changeMultiple SclerosisAug 30Shirley Ryan AbilityLabNCT07132775
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMultiple SclerosisAug 30Zenas BioPharma (USA), LLCNCT07067463
Added 6 new sites: Sofia, Bulgaria, Tbilisi, Georgia, Niš, Serbia and 3 more

Added 6 new sites: Sofia, Bulgaria, Tbilisi, Georgia, Niš, Serbia and 3 more

eligibility_changeMultiple SclerosisAug 30National Heart, Lung, and Blood Institute (NHLBI)NCT00001465
Eligibility criteria have been updated

Eligibility criteria have been updated

phase_changeMixed Connective Tissue DiseaseAug 30National Cancer Institute (NCI)NCT04616560
Moved from Phase 1, Phase 2 to Phase 2

Moved from Phase 1, Phase 2 to Phase 2

sites_addedMixed Connective Tissue DiseaseAug 30Children's Oncology GroupNCT02402244
Added 4 new sites: Peoria, Illinois, Norton Shores, Michigan, Tulsa, Oklahoma and 1 more

Added 4 new sites: Peoria, Illinois, Norton Shores, Michigan, Tulsa, Oklahoma and 1 more

Enrollment UpdateMesotheliomaAug 30M.D. Anderson Cancer CenterNCT03007030
Target enrollment decreased from 55 to 25

Target enrollment decreased from 55 to 25

sites_addedMembranous NephropathyAug 30BiogenNCT06962800
Added 1 new site: Shanghai, China

Added 1 new site: Shanghai, China

eligibility_changeLymphangioleiomyomatosisAug 29National Heart, Lung, and Blood Institute (NHLBI)NCT00001465
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedIdiopathic Pulmonary FibrosisAug 29PureTechNCT07284602
Added 1 new site: Reno, Nevada

Added 1 new site: Reno, Nevada

sites_addedIdiopathic Pulmonary FibrosisAug 29Reunion Neuroscience IncNCT07002034
Added 2 new sites: Chicago, Illinois, Worcester, Massachusetts

Added 2 new sites: Chicago, Illinois, Worcester, Massachusetts

sites_addedIdiopathic Pulmonary FibrosisAug 29Contineum TherapeuticsNCT07284459
Added 1 new site: Songpa-dong, South Korea

Added 1 new site: Songpa-dong, South Korea

sites_addedIdiopathic Pulmonary FibrosisAug 29AbbVieNCT07230288
Added 43 new sites: Birmingham, Alabama, Kissimmee, Florida, Ann Arbor, Michigan and 40 more

Added 43 new sites: Birmingham, Alabama, Kissimmee, Florida, Ann Arbor, Michigan and 40 more

sites_addedIdiopathic Pulmonary FibrosisAug 29Avalyn Pharma Inc.NCT06951217
Added 4 new sites: Seattle, Washington, Buenos Aires, Argentina, Buenos Aires, Argentina and 1 more

Added 4 new sites: Seattle, Washington, Buenos Aires, Argentina, Buenos Aires, Argentina and 1 more

sites_addedHypoparathyroidismAug 29MBX BiosciencesNCT07699471
Added 8 new sites: Los Angeles, California, Las Vegas, Nevada, Reno, Nevada and 5 more

Added 8 new sites: Los Angeles, California, Las Vegas, Nevada, Reno, Nevada and 5 more

sites_addedHypoparathyroidismAug 29Ascendis Pharma Bone Diseases A/SNCT07081997
Added 4 new sites: Chicago, Illinois, Minneota, Minnesota, Greenville, North Carolina and 1 more

Added 4 new sites: Chicago, Illinois, Minneota, Minnesota, Greenville, North Carolina and 1 more

sites_addedHodgkin LymphomaAug 29Regeneron PharmaceuticalsNCT06091865
Added 6 new sites: Curitiba, Brazil, Porto Alegre, Brazil, Porto Alegre, Brazil and 3 more

Added 6 new sites: Curitiba, Brazil, Porto Alegre, Brazil, Porto Alegre, Brazil and 3 more

sites_addedHodgkin LymphomaAug 29Merck Sharp & Dohme LLCNCT07570173
Added 2 new sites: Rotterdam, Netherlands, Stockholm, Sweden

Added 2 new sites: Rotterdam, Netherlands, Stockholm, Sweden

eligibility_changeHodgkin LymphomaAug 29Beijing InnoCare Pharma Tech Co., Ltd.NCT07082686
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedHodgkin LymphomaAug 29Curocell Inc.NCT04836507
Added 1 new site: Seoul, South Korea

Added 1 new site: Seoul, South Korea

eligibility_changeHodgkin LymphomaAug 29Curocell Inc.NCT04836507
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedHodgkin LymphomaAug 29Merck Sharp & Dohme LLCNCT07519772
Added 1 new site: Shanghai, China

Added 1 new site: Shanghai, China

sites_addedHodgkin LymphomaAug 29PfizerNCT03460977
Added 2 new sites: Bydgoszcz, Poland, Madrid, Spain

Added 2 new sites: Bydgoszcz, Poland, Madrid, Spain

sites_addedHodgkin LymphomaAug 29Bristol-Myers SquibbNCT06090539
Added 11 new sites: Nanchang, China, Nanchang, China, Shanghai, China and 8 more

Added 11 new sites: Nanchang, China, Nanchang, China, Shanghai, China and 8 more

eligibility_changeHodgkin LymphomaAug 29University of UtahNCT06227026
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedHodgkin LymphomaAug 29Thomas Helleday FoundationNCT04077307
Added 1 new site: Belgrade, Serbia

Added 1 new site: Belgrade, Serbia

Enrollment UpdateHodgkin LymphomaAug 29Thomas Helleday FoundationNCT04077307
Target enrollment increased from 9 to 50

Target enrollment increased from 9 to 50

sites_addedHodgkin LymphomaAug 29TORL Biotherapeutics, LLCNCT07439653
Added 3 new sites: Fullerton, California, Iowa City, Iowa, Dallas, Texas

Added 3 new sites: Fullerton, California, Iowa City, Iowa, Dallas, Texas

sites_addedHodgkin LymphomaAug 29National Cancer Institute (NCI)NCT07003295
Added 1 new site: Charlottesville, Virginia

Added 1 new site: Charlottesville, Virginia

sites_removedHodgkin LymphomaAug 29Fondazione Italiana Linfomi - ETSNCT05249959
Reduced from 21 to 19 sites

Reduced from 21 to 19 sites

Enrollment UpdateHodgkin LymphomaAug 29AbbVieNCT05512390
Target enrollment decreased from 154 to 39

Target enrollment decreased from 154 to 39

sites_addedHodgkin LymphomaAug 29AstraZenecaNCT06137118
Added 1 new site: Berlin, Germany

Added 1 new site: Berlin, Germany

eligibility_changeHodgkin LymphomaAug 29AstraZenecaNCT06137118
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedHodgkin LymphomaAug 29Lyell Immunopharma, Inc.NCT05826535
Added 1 new site: Nedlands, Australia

Added 1 new site: Nedlands, Australia

sites_addedHodgkin LymphomaAug 29LTZ Therapeutics, Inc.NCT07121946
Added 1 new site: New York, New York

Added 1 new site: New York, New York

sites_addedGranulomatosis with PolyangiitisAug 28University of PennsylvaniaNCT00315380
Added 2 new sites: Cambridge, United Kingdom, London, United Kingdom

Added 2 new sites: Cambridge, United Kingdom, London, United Kingdom

sites_addedHemophilia BAug 28CSL BehringNCT06003387
Added 1 new site: Houston, Texas

Added 1 new site: Houston, Texas

sites_addedGraves’ DiseaseAug 28Merida BiosciencesNCT07305818
Added 6 new sites: Torrance, California, Morehead City, North Carolina, DeSoto, Texas and 3 more

Added 6 new sites: Torrance, California, Morehead City, North Carolina, DeSoto, Texas and 3 more

sites_addedGraves’ DiseaseAug 28Immunovant Sciences GmbHNCT07018323
Added 3 new sites: Bergamo, Italy, Rome, Italy, Madrid, Spain

Added 3 new sites: Bergamo, Italy, Rome, Italy, Madrid, Spain

sites_addedGiant Cell ArteritisAug 28University Hospital, BrestNCT07279688
Added 1 new site: Pontoise, France

Added 1 new site: Pontoise, France

sites_addedGeographic AtrophyAug 28ONL TherapeuticsNCT06659445
Added 60 new sites: Linz, Austria, Vienna, Austria, Vienna, Austria and 57 more

Added 60 new sites: Linz, Austria, Vienna, Austria, Vienna, Austria and 57 more

eligibility_changeGeographic AtrophyAug 28Washington University School of MedicineNCT07174687
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedGeographic AtrophyAug 28i-Lumen Scientific AUS PTY LTDNCT06662162
Added 1 new site: Beachwood, Ohio

Added 1 new site: Beachwood, Ohio

eligibility_changeFocal Segmental GlomerulosclerosisAug 28National Human Genome Research Institute (NHGRI)NCT06664814
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeFamilial Chylomicronemia SyndromeAug 28Ionis Pharmaceuticals, Inc.NCT07727538
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedEssential ThrombocythemiaAug 28Novartis PharmaceuticalsNCT07357727
Added 4 new sites: Tainan, Taiwan, Ankara, Turkey (Türkiye), Ankara, Turkey (Türkiye) and 1 more

Added 4 new sites: Tainan, Taiwan, Ankara, Turkey (Türkiye), Ankara, Turkey (Türkiye) and 1 more

sites_removedChronic Graft-versus-Host DiseaseAug 27National Cancer Institute (NCI)NCT01886872
Reduced from 940 to 937 sites

Reduced from 940 to 937 sites

sites_addedChronic Graft-versus-Host DiseaseAug 27AmgenNCT07684235
Added 52 new sites: Anniston, Alabama, Mobile, Alabama, Fountain Valley, California and 49 more

Added 52 new sites: Anniston, Alabama, Mobile, Alabama, Fountain Valley, California and 49 more

sites_addedChronic Graft-versus-Host DiseaseAug 27AstraZenecaNCT07520162
Added 4 new sites: Bengbu, China, Hohhot, China, Shenyang, China and 1 more

Added 4 new sites: Bengbu, China, Hohhot, China, Shenyang, China and 1 more

sites_addedChronic Graft-versus-Host DiseaseAug 27Dianthus TherapeuticsNCT06858579
Added 18 new sites: New Haven, Connecticut, Buenos Aires, Argentina, Monza, Italy and 15 more

Added 18 new sites: New Haven, Connecticut, Buenos Aires, Argentina, Monza, Italy and 15 more

Enrollment UpdateChronic Graft-versus-Host DiseaseAug 27M.D. Anderson Cancer CenterNCT03128879
Target enrollment decreased from 90 to 59

Target enrollment decreased from 90 to 59

sites_addedChronic Graft-versus-Host DiseaseAug 27Novartis PharmaceuticalsNCT06632600
Added 1 new site: Porto Alegre, Brazil

Added 1 new site: Porto Alegre, Brazil

sites_removedChronic Graft-versus-Host DiseaseAug 27Alleviant Medical, Inc.NCT05685303
Reduced from 97 to 93 sites

Reduced from 97 to 93 sites

sites_addedChronic Graft-versus-Host DiseaseAug 27Medical College of WisconsinNCT04838041
Added 1 new site: Buffalo, New York

Added 1 new site: Buffalo, New York

sites_addedChronic Graft-versus-Host DiseaseAug 27AstraZenecaNCT07082738
Added 2 new sites: Missoula, Montana, Kusatsu-shi, Japan

Added 2 new sites: Missoula, Montana, Kusatsu-shi, Japan

sites_removedChronic Graft-versus-Host DiseaseAug 27Vastra Gotaland RegionNCT04561986
Reduced from 8 to 6 sites

Reduced from 8 to 6 sites

sites_removedChronic Graft-versus-Host DiseaseAug 27BeOne MedicinesNCT05006716
Reduced from 127 to 115 sites

Reduced from 127 to 115 sites

eligibility_changeChronic Graft-versus-Host DiseaseAug 27Fred Hutchinson Cancer CenterNCT07011810
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeChronic Graft-versus-Host DiseaseAug 27Wake Forest University Health SciencesNCT05828823
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_removedChronic Graft-versus-Host DiseaseAug 27Boehringer IngelheimNCT06935370
Reduced from 639 to 589 sites

Reduced from 639 to 589 sites

sites_addedCholangiocarcinomaAug 27BioNTech SENCT07186842
Added 1 new site: München, Germany

Added 1 new site: München, Germany

sites_addedDuchenne Muscular DystrophyAug 27Avidity Biosciences, Inc.NCT07587242
Added 1 new site: Liège, Belgium

Added 1 new site: Liège, Belgium

sites_addedDermatomyositisAug 27PfizerNCT06698796
Added 3 new sites: Frisco, Texas, Mendoza, Argentina, Gurugram, India

Added 3 new sites: Frisco, Texas, Mendoza, Argentina, Gurugram, India

sites_addedCushing DiseaseAug 27H. Lundbeck A/SNCT06471829
Added 16 new sites: Ann Arbor, Michigan, St Louis, Missouri, Bron, France and 13 more

Added 16 new sites: Ann Arbor, Michigan, St Louis, Missouri, Bron, France and 13 more

sites_removedCushing DiseaseAug 27Corcept TherapeuticsNCT03604198
Reduced from 48 to 44 sites

Reduced from 48 to 44 sites

sites_addedChronic Inflammatory Demyelinating PolyneuropathyAug 27argenxNCT07091630
Added 6 new sites: Philadelphia, Pennsylvania, Brasília, Brazil, Porto Alegre, Brazil and 3 more

Added 6 new sites: Philadelphia, Pennsylvania, Brasília, Brazil, Porto Alegre, Brazil and 3 more

sites_addedChronic Inflammatory Demyelinating PolyneuropathyAug 27SanofiNCT06290141
Added 6 new sites: New York, New York, Beaumont, Texas, Schwäbisch Hall, Germany and 3 more

Added 6 new sites: New York, New York, Beaumont, Texas, Schwäbisch Hall, Germany and 3 more

sites_addedChronic Inflammatory Demyelinating PolyneuropathyAug 27argenxNCT06920004
Added 7 new sites: Philadelphia, Pennsylvania, Philadelphia, Pennsylvania, São Paulo, Brazil and 4 more

Added 7 new sites: Philadelphia, Pennsylvania, Philadelphia, Pennsylvania, São Paulo, Brazil and 4 more

eligibility_changeChronic Granulomatous DiseaseAug 27EnsomaNCT06876363
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedChronic Graft-versus-Host DiseaseAug 27AstraZenecaNCT07633158
Added 3 new sites: Dortmund, Germany, Heilbronn, Germany, Jena, Germany

Added 3 new sites: Dortmund, Germany, Heilbronn, Germany, Jena, Germany

Enrollment UpdateChronic Graft-versus-Host DiseaseAug 27The Hong Kong Polytechnic UniversityNCT06973590
Target enrollment decreased from 80 to 60

Target enrollment decreased from 80 to 60

eligibility_changeChronic Graft-versus-Host DiseaseAug 27Chinese University of Hong KongNCT06715735
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedChronic Graft-versus-Host DiseaseAug 27SanofiNCT06859099
Added 2 new sites: Münster, Germany, Tlalnepantla, Mexico

Added 2 new sites: Münster, Germany, Tlalnepantla, Mexico

sites_addedChronic Graft-versus-Host DiseaseAug 27BeOne MedicinesNCT06973187
Added 32 new sites: Oakland, California, Roseville, California, San Francisco, California and 29 more

Added 32 new sites: Oakland, California, Roseville, California, San Francisco, California and 29 more

Enrollment UpdateChronic Graft-versus-Host DiseaseAug 27Duke-NUS Graduate Medical SchoolNCT05295368
Target enrollment decreased from 896 to 724

Target enrollment decreased from 896 to 724

Enrollment UpdateChronic Graft-versus-Host DiseaseAug 27Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06300320
Target enrollment increased from 52 to 65

Target enrollment increased from 52 to 65

sites_removedChronic Graft-versus-Host DiseaseAug 27BayerNCT05196035
Reduced from 164 to 132 sites

Reduced from 164 to 132 sites

sites_addedChronic Graft-versus-Host DiseaseAug 27Alliance for Clinical Trials in OncologyNCT07321652
Added 41 new sites: Panorama City, California, Miami Beach, Florida, Chicago, Illinois and 38 more

Added 41 new sites: Panorama City, California, Miami Beach, Florida, Chicago, Illinois and 38 more

eligibility_changeChronic Graft-versus-Host DiseaseAug 27SanofiNCT06914908
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedCholangiocarcinomaAug 27Astellas Pharma Global Development, Inc.NCT07488676
Added 3 new sites: Atlanta, Georgia, Hackensack, New Jersey, Fairfax, Virginia

Added 3 new sites: Atlanta, Georgia, Hackensack, New Jersey, Fairfax, Virginia

sites_addedCholangiocarcinomaAug 27AstraZenecaNCT07221253
Added 1 new site: Los Angeles, California

Added 1 new site: Los Angeles, California

sites_removedCholangiocarcinomaAug 27Hoffmann-La RocheNCT02568267
Reduced from 130 to 120 sites

Reduced from 130 to 120 sites

sites_addedCentral Diabetes InsipidusAug 27Children's Oncology GroupNCT06368817
Added 1 new site: Knoxville, Tennessee

Added 1 new site: Knoxville, Tennessee

sites_addedATTR Amyloidosis (Transthyretin Amyloidosis)Aug 26PfizerNCT06651073
Added 16 new sites: Hong Kong, Hong Kong, Kwai Chung, Hong Kong, Pok Fu Lam, Hong Kong and 13 more

Added 16 new sites: Hong Kong, Hong Kong, Kwai Chung, Hong Kong, Pok Fu Lam, Hong Kong and 13 more

eligibility_changeAmyotrophic Lateral SclerosisAug 26AC Immune SANCT06891716
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedBecker Muscular DystrophyAug 26Avidity Biosciences, Inc.NCT07587242
Added 1 new site: Liège, Belgium

Added 1 new site: Liège, Belgium

sites_addedAmyotrophic Lateral SclerosisAug 26Reunion Neuroscience IncNCT07002034
Added 2 new sites: Chicago, Illinois, Worcester, Massachusetts

Added 2 new sites: Chicago, Illinois, Worcester, Massachusetts

sites_addedAlpha-1 Antitrypsin DeficiencyAug 26AIRNA CorporationNCT07431112
Added 2 new sites: Matosinhos Municipality, Portugal, Barcelona, Spain

Added 2 new sites: Matosinhos Municipality, Portugal, Barcelona, Spain

sites_addedAlpha-1 Antitrypsin DeficiencyAug 26Tessera Therapeutics, Inc.NCT07227207
Added 1 new site: Nottingham, United Kingdom

Added 1 new site: Nottingham, United Kingdom

sites_addedAlagille SyndromeAug 26Digestive Care, Inc.NCT07335523
Added 5 new sites: New York, New York, Columbus, Ohio, Portland, Oregon and 2 more

Added 5 new sites: New York, New York, Columbus, Ohio, Portland, Oregon and 2 more

sites_removedAdrenocortical CarcinomaAug 26Corcept TherapeuticsNCT03604198
Reduced from 48 to 44 sites

Reduced from 48 to 44 sites

sites_addedAcromegalyAug 26Debiopharm International SANCT06930625
Added 1 new site: Krakow, Poland

Added 1 new site: Krakow, Poland

sites_addedAchondroplasiaAug 26BioMarin PharmaceuticalNCT07441876
Added 6 new sites: Hokkaido, Japan, Tokyo, Japan, Glasgow, United Kingdom and 3 more

Added 6 new sites: Hokkaido, Japan, Tokyo, Japan, Glasgow, United Kingdom and 3 more

sites_addedStargardt DiseaseAug 25Astellas Pharma Global Development, Inc.NCT07425574
Added 2 new sites: Miami, Florida, Cincinnati, Ohio

Added 2 new sites: Miami, Florida, Cincinnati, Ohio

sites_addedWild-Type ATTR Cardiac AmyloidosisAug 25AstraZenecaNCT06465810
Added 4 new sites: Baltimore, Maryland, Houston, Texas, Montreal, Canada and 1 more

Added 4 new sites: Baltimore, Maryland, Houston, Texas, Montreal, Canada and 1 more

sites_addedWaldenström MacroglobulinemiaAug 25BeOne MedicinesNCT05006716
Added 1 new site: Norwich, United Kingdom

Added 1 new site: Norwich, United Kingdom

sites_removedWaldenström MacroglobulinemiaAug 25Fondazione Italiana Linfomi - ETSNCT06441214
Reduced from 28 to 23 sites

Reduced from 28 to 23 sites

sites_addedWaldenström MacroglobulinemiaAug 25Eli Lilly and CompanyNCT07101328
Added 1 new site: Tokyo, Japan

Added 1 new site: Tokyo, Japan

sites_addedTurner SyndromeAug 25Ascendis Pharma A/SNCT07221851
Added 4 new sites: Montpellier, France, Düsseldorf, Germany, Trieste, Italy and 1 more

Added 4 new sites: Montpellier, France, Düsseldorf, Germany, Trieste, Italy and 1 more

eligibility_changeTuberous SclerosisAug 25National Heart, Lung, and Blood Institute (NHLBI)NCT00001465
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedThalassemiaAug 25Bristol-Myers SquibbNCT07215975
Added 12 new sites: Al Jahra, Kuwait, Andalusia, Kuwait, Kuwait City, Kuwait and 9 more

Added 12 new sites: Al Jahra, Kuwait, Andalusia, Kuwait, Kuwait City, Kuwait and 9 more

sites_addedSystemic Juvenile Idiopathic ArthritisAug 25Novartis PharmaceuticalsNCT07203001
Added 1 new site: Salt Lake City, Utah

Added 1 new site: Salt Lake City, Utah

Enrollment UpdateSpinal Muscular AtrophyAug 25BiogenNCT06555419
Target enrollment increased from 58 to 78

Target enrollment increased from 58 to 78

eligibility_changeSpinal Muscular AtrophyAug 25BiogenNCT06555419
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeSpinal Muscular AtrophyAug 25Alcyone Therapeutics, IncNCT05866419
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedSjögren's SyndromeAug 25Novartis PharmaceuticalsNCT05985915
Added 10 new sites: The Woodlands, Texas, Burgas, Bulgaria, Angers, France and 7 more

Added 10 new sites: The Woodlands, Texas, Burgas, Bulgaria, Angers, France and 7 more

sites_removedSickle Cell DiseaseAug 25Agios Pharmaceuticals, Inc.NCT06924970
Reduced from 30 to 20 sites

Reduced from 30 to 20 sites

eligibility_changeSickle Cell DiseaseAug 25National Heart, Lung, and Blood Institute (NHLBI)NCT05213572
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedSickle Cell DiseaseAug 25Novartis PharmaceuticalsNCT06439082
Added 2 new sites: Chicago, Illinois, Philadelphia, Pennsylvania

Added 2 new sites: Chicago, Illinois, Philadelphia, Pennsylvania

Enrollment UpdateSarcoidosisAug 24Xentria, Inc.NCT06169397
Target enrollment decreased from 94 to 31

Target enrollment decreased from 94 to 31

phase_changeSarcoidosisAug 24Priovant Therapeutics, Inc.NCT06978725
Moved from Phase 2 to Phase 2, Phase 3

Moved from Phase 2 to Phase 2, Phase 3

Enrollment UpdateSarcoidosisAug 24Priovant Therapeutics, Inc.NCT06978725
Target enrollment increased from 28 to 168

Target enrollment increased from 28 to 168

eligibility_changeSarcoidosisAug 24Priovant Therapeutics, Inc.NCT06978725
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedRett SyndromeAug 24Taysha Gene Therapies, Inc.NCT07480564
Added 2 new sites: Birmingham, Alabama, Chicago, Illinois

Added 2 new sites: Birmingham, Alabama, Chicago, Illinois

Enrollment UpdateRett SyndromeAug 24Taysha Gene Therapies, Inc.NCT07480564
Target enrollment increased from 3 to 4

Target enrollment increased from 3 to 4

sites_addedPulmonary Arterial HypertensionAug 24Duke UniversityNCT04278404
Added 1 new site: Houston, Texas

Added 1 new site: Houston, Texas

sites_addedPulmonary Arterial HypertensionAug 24University of PennsylvaniaNCT07132788
Added 1 new site: Providence, Rhode Island

Added 1 new site: Providence, Rhode Island

sites_addedPulmonary Arterial HypertensionAug 24Merck Sharp & Dohme LLCNCT07218029
Added 3 new sites: São Paulo, Brazil, Munich, Germany, Kfar Saba, Israel

Added 3 new sites: São Paulo, Brazil, Munich, Germany, Kfar Saba, Israel

sites_addedPulmonary Arterial HypertensionAug 24Regeneron PharmaceuticalsNCT07318597
Added 2 new sites: Boston, Massachusetts, Toledo, Spain

Added 2 new sites: Boston, Massachusetts, Toledo, Spain

sites_addedPulmonary Arterial HypertensionAug 24Insmed IncorporatedNCT07481981
Added 1 new site: Okayama, Japan

Added 1 new site: Okayama, Japan

sites_addedPulmonary Arterial HypertensionAug 24Tenax Therapeutics, Inc.NCT07288398
Added 49 new sites: Tucson, Arizona, Sacramento, California, San Francisco, California and 46 more

Added 49 new sites: Tucson, Arizona, Sacramento, California, San Francisco, California and 46 more

sites_addedPulmonary Arterial HypertensionAug 24Pulnovo Medical, Inc.NCT07214376
Added 3 new sites: Tucson, Arizona, Detroit, Michigan, Cleveland, Ohio

Added 3 new sites: Tucson, Arizona, Detroit, Michigan, Cleveland, Ohio

sites_addedProgressive Supranuclear PalsyAug 24Adam BoxerNCT07173803
Added 7 new sites: Palo Alto, California, San Diego, California, Boston, Massachusetts and 4 more

Added 7 new sites: Palo Alto, California, San Diego, California, Boston, Massachusetts and 4 more

sites_addedPrimary Biliary CholangitisAug 24Han YingNCT06174402
Added 2 new sites: Shenyang, China, Tianjin, China

Added 2 new sites: Shenyang, China, Tianjin, China

eligibility_changePrimary Biliary CholangitisAug 24Han YingNCT06174402
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedPrader-Willi SyndromeAug 24Soleno Therapeutics, Inc.NCT07450664
Added 1 new site: Salt Lake City, Utah

Added 1 new site: Salt Lake City, Utah

sites_addedPolycythemia VeraAug 24Novartis PharmaceuticalsNCT07357727
Added 18 new sites: New Haven, Connecticut, Atlanta, Georgia, CABA, Argentina and 15 more

Added 18 new sites: New Haven, Connecticut, Atlanta, Georgia, CABA, Argentina and 15 more

sites_addedPolycythemia VeraAug 24Ono Pharmaceutical Co., Ltd.NCT07429266
Added 2 new sites: Grand Rapids, Michigan, West Perth, Australia

Added 2 new sites: Grand Rapids, Michigan, West Perth, Australia

sites_addedPhenylketonuriaAug 24Maze TherapeuticsNCT07694440
Added 4 new sites: Oakland, California, Palo Alto, California, Lexington, Kentucky and 1 more

Added 4 new sites: Oakland, California, Palo Alto, California, Lexington, Kentucky and 1 more

sites_addedParoxysmal Nocturnal HemoglobinuriaAug 24Hoffmann-La RocheNCT04434092
Added 2 new sites: George Town, Malaysia, Kuantan, Malaysia

Added 2 new sites: George Town, Malaysia, Kuantan, Malaysia

sites_addedNoonan SyndromeAug 23Ascendis Pharma A/SNCT07221851
Added 4 new sites: Montpellier, France, Düsseldorf, Germany, Trieste, Italy and 1 more

Added 4 new sites: Montpellier, France, Düsseldorf, Germany, Trieste, Italy and 1 more

sites_addedNarcolepsy Type 1Aug 23TakedaNCT07646678
Added 12 new sites: Brandon, Florida, Miami, Florida, Atlanta, Georgia and 9 more

Added 12 new sites: Brandon, Florida, Miami, Florida, Atlanta, Georgia and 9 more

sites_addedMyotonic DystrophyAug 23Dyne TherapeuticsNCT07486934
Added 1 new site: Nijmegen, Netherlands

Added 1 new site: Nijmegen, Netherlands

sites_addedMyotonic DystrophyAug 23Avidity Biosciences, Inc.NCT07587242
Added 1 new site: Leuven, Belgium

Added 1 new site: Leuven, Belgium

sites_addedMyelofibrosisAug 23Novartis PharmaceuticalsNCT07357727
Added 18 new sites: New Haven, Connecticut, Atlanta, Georgia, CABA, Argentina and 15 more

Added 18 new sites: New Haven, Connecticut, Atlanta, Georgia, CABA, Argentina and 15 more

Enrollment UpdateMyelodysplastic SyndromesAug 23Franziska WachterNCT05796570
Target enrollment decreased from 37 to 29

Target enrollment decreased from 37 to 29

sites_addedMyelodysplastic SyndromesAug 23TakedaNCT04419649
Added 6 new sites: Hot Springs, Arkansas, Bethesda, Maryland, Hackensack, New Jersey and 3 more

Added 6 new sites: Hot Springs, Arkansas, Bethesda, Maryland, Hackensack, New Jersey and 3 more

eligibility_changeMyelodysplastic SyndromesAug 23Vanderbilt-Ingram Cancer CenterNCT06399640
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMyelodysplastic SyndromesAug 23Beijing InnoCare Pharma Tech Co., Ltd.NCT06656494
Added 4 new sites: Orange, California, Tampa, Florida, Chapel Hill, North Carolina and 1 more

Added 4 new sites: Orange, California, Tampa, Florida, Chapel Hill, North Carolina and 1 more

sites_addedMyelodysplastic SyndromesAug 23National Cancer Institute (NCI)NCT06577441
Added 1 new site: Lebanon, New Hampshire

Added 1 new site: Lebanon, New Hampshire

sites_removedMyelodysplastic SyndromesAug 23TakedaNCT06499285
Reduced from 179 to 177 sites

Reduced from 179 to 177 sites

sites_addedMyelodysplastic SyndromesAug 23Hoffmann-La RocheNCT04434092
Added 2 new sites: George Town, Malaysia, Kuantan, Malaysia

Added 2 new sites: George Town, Malaysia, Kuantan, Malaysia

sites_addedMyasthenia GravisAug 23argenxNCT07294170
Added 3 new sites: Göttingen, Germany, Würzburg, Germany, Hanamaki, Japan

Added 3 new sites: Göttingen, Germany, Würzburg, Germany, Hanamaki, Japan

sites_addedMyasthenia GravisAug 23argenxNCT07673627
Added 1 new site: Amherst, New York

Added 1 new site: Amherst, New York

sites_addedMyasthenia GravisAug 23TG Therapeutics, Inc.NCT07673744
Added 2 new sites: Farmington Hills, Michigan, New Bern, North Carolina

Added 2 new sites: Farmington Hills, Michigan, New Bern, North Carolina

sites_addedMyasthenia GravisAug 23argenxNCT07284420
Added 3 new sites: Göttingen, Germany, Würzburg, Germany, Hanamaki, Japan

Added 3 new sites: Göttingen, Germany, Würzburg, Germany, Hanamaki, Japan

sites_addedMultiple System AtrophyAug 23BiogenNCT07221669
Added 4 new sites: Randwick, Australia, Porto Alegre, Brazil, Sai Paula, Brazil and 1 more

Added 4 new sites: Randwick, Australia, Porto Alegre, Brazil, Sai Paula, Brazil and 1 more

eligibility_changeMultiple SclerosisAug 23Luzerner KantonsspitalNCT07256704
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMultiple SclerosisAug 23Novartis PharmaceuticalsNCT05147220
Added 6 new sites: Santiago del Estero, Argentina, Zagreb, Croatia, Dublin, Ireland and 3 more

Added 6 new sites: Santiago del Estero, Argentina, Zagreb, Croatia, Dublin, Ireland and 3 more

sites_removedMultiple SclerosisAug 23Genentech, Inc.NCT07609719
Reduced from 11 to 1 sites

Reduced from 11 to 1 sites

eligibility_changeMultiple SclerosisAug 23Genentech, Inc.NCT07609719
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMultiple SclerosisAug 23Hoffmann-La RocheNCT07282574
Added 5 new sites: Camperdown, Australia, Mannheim, Germany, Essen, Germany and 2 more

Added 5 new sites: Camperdown, Australia, Mannheim, Germany, Essen, Germany and 2 more

sites_addedMultiple SclerosisAug 23Zenas BioPharma (USA), LLCNCT07299019
Added 4 new sites: Zagreb, Croatia, Bydgoszcz, Poland, Poznan, Poland and 1 more

Added 4 new sites: Zagreb, Croatia, Bydgoszcz, Poland, Poznan, Poland and 1 more

sites_addedMultiple SclerosisAug 23Novartis PharmaceuticalsNCT06655896
Added 3 new sites: Córdoba, Argentina, Monterrey, Mexico, Seoul, South Korea

Added 3 new sites: Córdoba, Argentina, Monterrey, Mexico, Seoul, South Korea

sites_addedMultiple SclerosisAug 23Zenas BioPharma (USA), LLCNCT07067463
Added 1 new site: Bydgoszcz, Poland

Added 1 new site: Bydgoszcz, Poland

sites_addedMultiple SclerosisAug 23OculisNCT07623668
Added 2 new sites: Charleston, South Carolina, Dallas, Texas

Added 2 new sites: Charleston, South Carolina, Dallas, Texas

sites_addedMultiple SclerosisAug 23CelgeneNCT06782490
Added 2 new sites: Philadelphia, Pennsylvania, Lewisville, Texas

Added 2 new sites: Philadelphia, Pennsylvania, Lewisville, Texas

eligibility_changeMultiple SclerosisAug 23National Heart, Lung, and Blood Institute (NHLBI)NCT00001465
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMultiple SclerosisAug 23Novartis PharmaceuticalsNCT05156281
Added 8 new sites: Zagreb, Croatia, Vukovar, Croatia, Chiba, Japan and 5 more

Added 8 new sites: Zagreb, Croatia, Vukovar, Croatia, Chiba, Japan and 5 more

sites_addedMultiple SclerosisAug 23TG Therapeutics, Inc.NCT05877963
Added 3 new sites: Atlanta, Georgia, Atlanta, Georgia, Cincinnati, Ohio

Added 3 new sites: Atlanta, Georgia, Atlanta, Georgia, Cincinnati, Ohio

eligibility_changeMultiple Endocrine Neoplasia Type 1Aug 23Shehzad Basaria, M.D.NCT06957691
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeMixed Connective Tissue DiseaseAug 23Mayo ClinicNCT05269381
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeMerkel Cell CarcinomaAug 23M.D. Anderson Cancer CenterNCT02479698
Eligibility criteria have been updated

Eligibility criteria have been updated

Enrollment UpdateMerkel Cell CarcinomaAug 23AstraZenecaNCT07115043
Target enrollment increased from 60 to 120

Target enrollment increased from 60 to 120

eligibility_changeMerkel Cell CarcinomaAug 23Mayo ClinicNCT05269381
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMembranous NephropathyAug 23BiogenNCT06962800
Added 7 new sites: São Paulo, Brazil, Vancouver, Canada, Shenzhen, China and 4 more

Added 7 new sites: São Paulo, Brazil, Vancouver, Canada, Shenzhen, China and 4 more

eligibility_changeLymphangioleiomyomatosisAug 22National Heart, Lung, and Blood Institute (NHLBI)NCT00001465
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedLight Chain AmyloidosisAug 22Regeneron PharmaceuticalsNCT06292780
Added 1 new site: Taipei, Taiwan

Added 1 new site: Taipei, Taiwan

sites_addedLight Chain AmyloidosisAug 22Dana-Farber Cancer InstituteNCT06569147
Added 4 new sites: New Haven, Connecticut, Boston, Massachusetts, Boston, Massachusetts and 1 more

Added 4 new sites: New Haven, Connecticut, Boston, Massachusetts, Boston, Massachusetts and 1 more

sites_addedLennox-Gastaut SyndromeAug 22EpygenixNCT05066217
Added 33 new sites: Orlando, Florida, Beijing, China, Beijing, China and 30 more

Added 33 new sites: Orlando, Florida, Beijing, China, Beijing, China and 30 more

sites_addedKawasaki DiseaseAug 22Duke UniversityNCT04278404
Added 1 new site: Houston, Texas

Added 1 new site: Houston, Texas

sites_addedIgA NephropathyAug 22Jade Biosciences, Inc.NCT07541287
Added 5 new sites: Concord, Australia, Anyang-si, South Korea, Seongnam-si, South Korea and 2 more

Added 5 new sites: Concord, Australia, Anyang-si, South Korea, Seongnam-si, South Korea and 2 more

sites_addedIgA NephropathyAug 22BiogenNCT06935357
Added 2 new sites: Hong Kong, China, Hong Kong, China

Added 2 new sites: Hong Kong, China, Hong Kong, China

sites_addedIgA NephropathyAug 22Novartis PharmaceuticalsNCT06858319
Added 5 new sites: Iowa City, Iowa, Gosford, Australia, Monterrey, Mexico and 2 more

Added 5 new sites: Iowa City, Iowa, Gosford, Australia, Monterrey, Mexico and 2 more

sites_removedIdiopathic Pulmonary FibrosisAug 22Vicore Pharma ABNCT06588686
Reduced from 111 to 104 sites

Reduced from 111 to 104 sites

sites_addedIdiopathic Pulmonary FibrosisAug 22Contineum TherapeuticsNCT07284459
Added 4 new sites: Mar del Plata, Argentina, Quilmes, Argentina, Québec, Canada and 1 more

Added 4 new sites: Mar del Plata, Argentina, Quilmes, Argentina, Québec, Canada and 1 more

sites_addedHuntington DiseaseAug 22Skyhawk Therapeutics, Inc.NCT07378644
Added 4 new sites: Englewood, Colorado, São Paulo, Brazil, Santiago, Chile and 1 more

Added 4 new sites: Englewood, Colorado, São Paulo, Brazil, Santiago, Chile and 1 more

sites_addedHodgkin LymphomaAug 22National Cancer Institute (NCI)NCT04840602
Added 2 new sites: Detroit, Michigan, Farmington Hills, Michigan

Added 2 new sites: Detroit, Michigan, Farmington Hills, Michigan

sites_removedHodgkin LymphomaAug 22Etan OrgelNCT05082519
Reduced from 20 to 16 sites

Reduced from 20 to 16 sites

eligibility_changeHodgkin LymphomaAug 22Etan OrgelNCT05082519
Eligibility criteria have been updated

Eligibility criteria have been updated

Enrollment UpdateHodgkin LymphomaAug 22Janssen Research & Development, LLCNCT05421663
Target enrollment decreased from 439 to 166

Target enrollment decreased from 439 to 166

sites_addedHodgkin LymphomaAug 22Allogene TherapeuticsNCT06500273
Added 8 new sites: Minneapolis, Minnesota, Goyang-si, South Korea, Hwasun, South Korea and 5 more

Added 8 new sites: Minneapolis, Minnesota, Goyang-si, South Korea, Hwasun, South Korea and 5 more

Enrollment UpdateHodgkin LymphomaAug 22Children's Oncology GroupNCT03007147
Target enrollment decreased from 475 to 352

Target enrollment decreased from 475 to 352

sites_addedHodgkin LymphomaAug 22BeOne MedicinesNCT05006716
Added 1 new site: Norwich, United Kingdom

Added 1 new site: Norwich, United Kingdom

sites_addedHodgkin LymphomaAug 22Merck Sharp & Dohme LLCNCT07519772
Added 12 new sites: Townsville, Australia, Box Hill, Australia, Toronto, Canada and 9 more

Added 12 new sites: Townsville, Australia, Box Hill, Australia, Toronto, Canada and 9 more

Enrollment UpdateHodgkin LymphomaAug 22Merck Sharp & Dohme LLCNCT07519772
Target enrollment increased from 200 to 280

Target enrollment increased from 200 to 280

sites_addedHodgkin LymphomaAug 22University of WashingtonNCT06745076
Added 1 new site: Palo Alto, California

Added 1 new site: Palo Alto, California

sites_addedHodgkin LymphomaAug 22Merck Sharp & Dohme LLCNCT07570173
Added 6 new sites: Athens, Greece, Athens, Greece, Ioannina, Greece and 3 more

Added 6 new sites: Athens, Greece, Athens, Greece, Ioannina, Greece and 3 more

sites_removedHodgkin LymphomaAug 22BeOne MedicinesNCT05100862
Reduced from 268 to 266 sites

Reduced from 268 to 266 sites

sites_addedHodgkin LymphomaAug 22Merck Sharp & Dohme LLCNCT07634471
Added 2 new sites: Córdoba, Argentina, Box Hill, Australia

Added 2 new sites: Córdoba, Argentina, Box Hill, Australia

sites_addedHodgkin LymphomaAug 22Vironexis Biotherapeutics Inc.NCT06533579
Added 2 new sites: Jacksonville, Florida, Rochester, Minnesota

Added 2 new sites: Jacksonville, Florida, Rochester, Minnesota

eligibility_changeHodgkin LymphomaAug 22Roswell Park Cancer InstituteNCT06863402
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeHodgkin LymphomaAug 22National Cancer Institute (NCI)NCT01896999
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedHodgkin LymphomaAug 22Alliance for Clinical Trials in OncologyNCT05976763
Added 1 new site: Mount Vernon, Illinois

Added 1 new site: Mount Vernon, Illinois

sites_addedHodgkin LymphomaAug 22Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.NCT06980116
Added 8 new sites: Athens, Greece, Pátrai, Greece, Thessaloniki, Greece and 5 more

Added 8 new sites: Athens, Greece, Pátrai, Greece, Thessaloniki, Greece and 5 more

sites_addedHereditary Hemorrhagic TelangiectasiaAug 22Atavistik Bio, IncNCT07601425
Added 1 new site: Rochester, Minnesota

Added 1 new site: Rochester, Minnesota

sites_addedHemophilia AAug 21Duke UniversityNCT04278404
Added 1 new site: Houston, Texas

Added 1 new site: Houston, Texas

sites_addedGraves’ DiseaseAug 21argenxNCT07596849
Added 5 new sites: Surrey, Canada, Kawasaki, Japan, Kitakyushu, Japan and 2 more

Added 5 new sites: Surrey, Canada, Kawasaki, Japan, Kitakyushu, Japan and 2 more

sites_addedGraves’ DiseaseAug 21BiogenNCT07722546
Added 2 new sites: Los Angeles, California, Asheville, North Carolina

Added 2 new sites: Los Angeles, California, Asheville, North Carolina

sites_addedEssential ThrombocythemiaAug 21Novartis PharmaceuticalsNCT07357727
Added 2 new sites: Shanghai, China, Kuching, Malaysia

Added 2 new sites: Shanghai, China, Kuching, Malaysia

sites_addedHemophilia BAug 21American Thrombosis and Hemostasis NetworkNCT04398628
Added 5 new sites: Miami, Florida, Tampa, Florida, Columbus, Ohio and 2 more

Added 5 new sites: Miami, Florida, Tampa, Florida, Columbus, Ohio and 2 more

sites_addedHemophilia AAug 21American Thrombosis and Hemostasis NetworkNCT04398628
Added 5 new sites: Miami, Florida, Tampa, Florida, Columbus, Ohio and 2 more

Added 5 new sites: Miami, Florida, Tampa, Florida, Columbus, Ohio and 2 more

sites_addedGraves’ DiseaseAug 21Viridian Therapeutics, Inc.NCT06625398
Added 24 new sites: San Diego, California, Berlin, Germany, Dresden, Germany and 21 more

Added 24 new sites: San Diego, California, Berlin, Germany, Dresden, Germany and 21 more

sites_addedGraves’ DiseaseAug 21Viridian Therapeutics, Inc.NCT06625411
Added 15 new sites: San Diego, California, Berlin, Germany, Dresden, Germany and 12 more

Added 15 new sites: San Diego, California, Berlin, Germany, Dresden, Germany and 12 more

sites_addedGlycogen Storage Disease Type IIAug 21Denali Therapeutics Inc.NCT07354724
Added 1 new site: St Louis, Missouri

Added 1 new site: St Louis, Missouri

sites_addedGiant Cell ArteritisAug 21University of PennsylvaniaNCT04474847
Added 1 new site: Kirchheim unter Teck, Germany

Added 1 new site: Kirchheim unter Teck, Germany

eligibility_changeGeographic AtrophyAug 21Novartis PharmaceuticalsNCT07441642
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedGeographic AtrophyAug 21Perceive Biotherapeutics, Inc.NCT06087458
Added 8 new sites: Poway, California, Boston, Massachusetts, St Louis, Missouri and 5 more

Added 8 new sites: Poway, California, Boston, Massachusetts, St Louis, Missouri and 5 more

sites_removedGaucher DiseaseAug 21Prevail TherapeuticsNCT05487599
Reduced from 9 to 5 sites

Reduced from 9 to 5 sites

Enrollment UpdateGaucher DiseaseAug 21Prevail TherapeuticsNCT05487599
Target enrollment decreased from 15 to 8

Target enrollment decreased from 15 to 8

sites_addedGaucher DiseaseAug 21Prevail TherapeuticsNCT04411654
Added 1 new site: New York, New York

Added 1 new site: New York, New York

sites_addedFocal Segmental GlomerulosclerosisAug 21Boehringer IngelheimNCT07220083
Added 5 new sites: Olympia Fields, Illinois, Dallas, Texas, San Miguel de Tucumán, Argentina and 2 more

Added 5 new sites: Olympia Fields, Illinois, Dallas, Texas, San Miguel de Tucumán, Argentina and 2 more

sites_addedFamilial Chylomicronemia SyndromeAug 21Ionis Pharmaceuticals, Inc.NCT07727538
Added 1 new site: Birmingham, Alabama

Added 1 new site: Birmingham, Alabama

Enrollment UpdateFabry DiseaseAug 21Sangamo TherapeuticsNCT05039866
Target enrollment decreased from 48 to 32

Target enrollment decreased from 48 to 32

sites_addedEssential ThrombocythemiaAug 21Novartis PharmaceuticalsNCT07357727
Added 16 new sites: New Haven, Connecticut, Atlanta, Georgia, CABA, Argentina and 13 more

Added 16 new sites: New Haven, Connecticut, Atlanta, Georgia, CABA, Argentina and 13 more

Enrollment UpdateInherited ErythromelalgiaAug 21St. Olavs HospitalNCT04039633
Target enrollment decreased from 24 to 6

Target enrollment decreased from 24 to 6

sites_addedEosinophilic EsophagitisAug 20Regeneron PharmaceuticalsNCT07112378
Added 1 new site: Seattle, Washington

Added 1 new site: Seattle, Washington

eligibility_changeDilated CardiomyopathyAug 20Affinia TherapeuticsNCT07426419
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedChronic Graft-versus-Host DiseaseAug 20VA Office of Research and DevelopmentNCT05194930
Added 1 new site: Miami, Florida

Added 1 new site: Miami, Florida

sites_addedChronic Graft-versus-Host DiseaseAug 20AstraZenecaNCT07481526
Added 59 new sites: Anning, Yunnan - South Region, China, Beijing, Beijing, China, Cangzhou, Hebei - North Region, China and 56 more

Added 59 new sites: Anning, Yunnan - South Region, China, Beijing, Beijing, China, Cangzhou, Hebei - North Region, China and 56 more

sites_addedChronic Graft-versus-Host DiseaseAug 20AstraZenecaNCT07288515
Added 2 new sites: Grodno, Belarus, Homyel, Belarus

Added 2 new sites: Grodno, Belarus, Homyel, Belarus

sites_addedChronic Graft-versus-Host DiseaseAug 20argenxNCT07194850
Added 11 new sites: Bordeaux, France, Freiburg im Breisgau, Germany, Monza, Italy and 8 more

Added 11 new sites: Bordeaux, France, Freiburg im Breisgau, Germany, Monza, Italy and 8 more

sites_removedChronic Graft-versus-Host DiseaseAug 20Merck Sharp & Dohme LLCNCT05947851
Reduced from 55 to 52 sites

Reduced from 55 to 52 sites

sites_addedChronic Graft-versus-Host DiseaseAug 20Hoffmann-La RocheNCT04544449
Added 3 new sites: Capital Federal, Argentina, Braga, Portugal, Zaporizhzhya, Ukraine

Added 3 new sites: Capital Federal, Argentina, Braga, Portugal, Zaporizhzhya, Ukraine

sites_addedChronic Graft-versus-Host DiseaseAug 20Novartis PharmaceuticalsNCT06858319
Added 5 new sites: Iowa City, Iowa, Gosford, Australia, Monterrey, Mexico and 2 more

Added 5 new sites: Iowa City, Iowa, Gosford, Australia, Monterrey, Mexico and 2 more

sites_addedChronic Graft-versus-Host DiseaseAug 20Novartis PharmaceuticalsNCT06799000
Added 3 new sites: Sofia, Bulgaria, Stara Zagora, Bulgaria, Trnava, Slovakia

Added 3 new sites: Sofia, Bulgaria, Stara Zagora, Bulgaria, Trnava, Slovakia

sites_addedChronic Graft-versus-Host DiseaseAug 20UCB Biopharma SRLNCT07725939
Added 2 new sites: Columbus, Ohio, DuBois, Pennsylvania

Added 2 new sites: Columbus, Ohio, DuBois, Pennsylvania

sites_addedChronic Graft-versus-Host DiseaseAug 20Hoffmann-La RocheNCT07282574
Added 5 new sites: Camperdown, Australia, Mannheim, Germany, Essen, Germany and 2 more

Added 5 new sites: Camperdown, Australia, Mannheim, Germany, Essen, Germany and 2 more

sites_addedChronic Graft-versus-Host DiseaseAug 20Artivion Inc.NCT07089576
Added 5 new sites: Birmingham, Alabama, Washington D.C., District of Columbia, Gainesville, Florida and 2 more

Added 5 new sites: Birmingham, Alabama, Washington D.C., District of Columbia, Gainesville, Florida and 2 more

sites_addedDuchenne Muscular DystrophyAug 20Avidity Biosciences, Inc.NCT07587242
Added 1 new site: Leuven, Belgium

Added 1 new site: Leuven, Belgium

sites_addedDuchenne Muscular DystrophyAug 20University of RochesterNCT07092540
Added 3 new sites: Stony Brook, New York, Cincinnati, Ohio, Columbus, Ohio

Added 3 new sites: Stony Brook, New York, Cincinnati, Ohio, Columbus, Ohio

sites_addedDilated CardiomyopathyAug 20Alexion Pharmaceuticals, Inc.NCT07218887
Added 1 new site: Palo Alto, California

Added 1 new site: Palo Alto, California

eligibility_changeDilated CardiomyopathyAug 20Alexion Pharmaceuticals, Inc.NCT07218887
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedDermatomyositisAug 20Cartesian TherapeuticsNCT07391605
Added 4 new sites: Orange, California, Boston, Massachusetts, Chapel Hill, North Carolina and 1 more

Added 4 new sites: Orange, California, Boston, Massachusetts, Chapel Hill, North Carolina and 1 more

Enrollment UpdateDermatomyositisAug 20National Institute of Environmental Health Sciences (NIEHS)NCT07111065
Target enrollment increased from 300 to 3000

Target enrollment increased from 300 to 3000

sites_addedCystic FibrosisAug 20University of PennsylvaniaNCT06950892
Added 1 new site: Spokane, Washington

Added 1 new site: Spokane, Washington

Enrollment UpdateCystic FibrosisAug 20ReCode TherapeuticsNCT06237335
Target enrollment decreased from 192 to 128

Target enrollment decreased from 192 to 128

sites_addedChronic Inflammatory Demyelinating PolyneuropathyAug 20Dianthus TherapeuticsNCT06858579
Added 7 new sites: Buenos Aires, Argentina, Monza, Italy, Salerno, Italy and 4 more

Added 7 new sites: Buenos Aires, Argentina, Monza, Italy, Salerno, Italy and 4 more

sites_addedChronic Inflammatory Demyelinating PolyneuropathyAug 20Kite, A Gilead CompanyNCT07304154
Added 2 new sites: Newport Beach, California, Montreal, Canada

Added 2 new sites: Newport Beach, California, Montreal, Canada

eligibility_changeChronic Granulomatous DiseaseAug 20National Institute of Allergy and Infectious Diseases (NIAID)NCT07113743
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_removedChronic Graft-versus-Host DiseaseAug 20BeOne MedicinesNCT06970743
Reduced from 64 to 56 sites

Reduced from 64 to 56 sites

eligibility_changeChronic Graft-versus-Host DiseaseAug 20BeOne MedicinesNCT06970743
Eligibility criteria have been updated

Eligibility criteria have been updated

Enrollment UpdateChronic Graft-versus-Host DiseaseAug 20National Institute of Allergy and Infectious Diseases (NIAID)NCT06325709
Target enrollment increased from 10 to 15

Target enrollment increased from 10 to 15

eligibility_changeChronic Graft-versus-Host DiseaseAug 20National Institute of Allergy and Infectious Diseases (NIAID)NCT06325709
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedChronic Graft-versus-Host DiseaseAug 20Gan LijunNCT07587099
Added 11 new sites: Beijing, China, Haikou, China, Harbin, China and 8 more

Added 11 new sites: Beijing, China, Haikou, China, Harbin, China and 8 more

sites_addedChronic Graft-versus-Host DiseaseAug 20Zura Bio IncNCT06993610
Added 5 new sites: Hollywood, Florida, Fargo, North Dakota, Dallas, Texas and 2 more

Added 5 new sites: Hollywood, Florida, Fargo, North Dakota, Dallas, Texas and 2 more

sites_removedChronic Graft-versus-Host DiseaseAug 20Hoffmann-La RocheNCT05878769
Reduced from 486 to 481 sites

Reduced from 486 to 481 sites

sites_addedChronic Graft-versus-Host DiseaseAug 20Boehringer IngelheimNCT06531824
Added 20 new sites: Brookhaven, Mississippi, Philadelphia, Pennsylvania, Catamarca, Argentina and 17 more

Added 20 new sites: Brookhaven, Mississippi, Philadelphia, Pennsylvania, Catamarca, Argentina and 17 more

eligibility_changeChronic Graft-versus-Host DiseaseAug 20Boehringer IngelheimNCT06531824
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedChronic Graft-versus-Host DiseaseAug 20AstraZenecaNCT07069829
Added 15 new sites: Buenos Aires, Argentina, La Plata, Argentina, Mar del Plata, Argentina and 12 more

Added 15 new sites: Buenos Aires, Argentina, La Plata, Argentina, Mar del Plata, Argentina and 12 more

sites_addedChronic Graft-versus-Host DiseaseAug 20GlaxoSmithKlineNCT07177339
Added 112 new sites: Newport Beach, California, Lakewood, Colorado, Brandon, Florida and 109 more

Added 112 new sites: Newport Beach, California, Lakewood, Colorado, Brandon, Florida and 109 more

sites_addedChronic Graft-versus-Host DiseaseAug 20Monash UniversityNCT05072314
Added 2 new sites: Bentley, Australia, Winchester, United Kingdom

Added 2 new sites: Bentley, Australia, Winchester, United Kingdom

Enrollment UpdateChronic Graft-versus-Host DiseaseAug 20AbbVieNCT02966756
Target enrollment decreased from 110 to 66

Target enrollment decreased from 110 to 66

Enrollment UpdateChronic Graft-versus-Host DiseaseAug 20St. Olavs HospitalNCT05372822
Target enrollment increased from 50 to 87

Target enrollment increased from 50 to 87

sites_addedChronic Graft-versus-Host DiseaseAug 20Incyte CorporationNCT06585774
Added 1 new site: Duarte, California

Added 1 new site: Duarte, California

sites_removedChronic Graft-versus-Host DiseaseAug 20Alexion Pharmaceuticals, Inc.NCT06291376
Reduced from 267 to 246 sites

Reduced from 267 to 246 sites

Enrollment UpdateChronic Graft-versus-Host DiseaseAug 20Alexion Pharmaceuticals, Inc.NCT06291376
Target enrollment increased from 510 to 579

Target enrollment increased from 510 to 579

eligibility_changeChronic Graft-versus-Host DiseaseAug 20Alexion Pharmaceuticals, Inc.NCT06291376
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedChronic Graft-versus-Host DiseaseAug 20CSL BehringNCT05485961
Added 11 new sites: Pomona, California, Santa Fe, Argentina, Salvador, Brazil and 8 more

Added 11 new sites: Pomona, California, Santa Fe, Argentina, Salvador, Brazil and 8 more

eligibility_changeChronic Graft-versus-Host DiseaseAug 20CSL BehringNCT05485961
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeChronic Graft-versus-Host DiseaseAug 20Alcyone Therapeutics, IncNCT05866419
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeCholangiocarcinomaAug 20M.D. Anderson Cancer CenterNCT06439485
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedCharcot-Marie-Tooth DiseaseAug 20Novartis PharmaceuticalsNCT05147220
Added 6 new sites: Santiago del Estero, Argentina, Zagreb, Croatia, Dublin, Ireland and 3 more

Added 6 new sites: Santiago del Estero, Argentina, Zagreb, Croatia, Dublin, Ireland and 3 more

sites_addedCharcot-Marie-Tooth DiseaseAug 20Novartis PharmaceuticalsNCT05156281
Added 8 new sites: Zagreb, Croatia, Vukovar, Croatia, Chiba, Japan and 5 more

Added 8 new sites: Zagreb, Croatia, Vukovar, Croatia, Chiba, Japan and 5 more

sites_addedBecker Muscular DystrophyAug 19University of RochesterNCT07092540
Added 3 new sites: Stony Brook, New York, Cincinnati, Ohio, Columbus, Ohio

Added 3 new sites: Stony Brook, New York, Cincinnati, Ohio, Columbus, Ohio

sites_addedATTR Amyloidosis (Transthyretin Amyloidosis)Aug 19AstraZenecaNCT06465810
Added 4 new sites: Baltimore, Maryland, Houston, Texas, Montreal, Canada and 1 more

Added 4 new sites: Baltimore, Maryland, Houston, Texas, Montreal, Canada and 1 more

sites_addedATTR Amyloidosis (Transthyretin Amyloidosis)Aug 19Novo Nordisk A/SNCT07207811
Added 4 new sites: Baltimore, Maryland, Guiyang, China, Jinan, China and 1 more

Added 4 new sites: Baltimore, Maryland, Guiyang, China, Jinan, China and 1 more

eligibility_changeATTR Amyloidosis (Transthyretin Amyloidosis)Aug 19Novo Nordisk A/SNCT07207811
Eligibility criteria have been updated

Eligibility criteria have been updated

Enrollment UpdateAlpha-1 Antitrypsin DeficiencyAug 19Alpha-1 FoundationNCT04157049
Target enrollment increased from 4000 to 5000

Target enrollment increased from 4000 to 5000

sites_addedBecker Muscular DystrophyAug 19Avidity Biosciences, Inc.NCT07587242
Added 1 new site: Leuven, Belgium

Added 1 new site: Leuven, Belgium

sites_addedBecker Muscular DystrophyAug 19Solid Biosciences Inc.NCT07160634
Added 1 new site: Toronto, Canada

Added 1 new site: Toronto, Canada

eligibility_changeBecker Muscular DystrophyAug 19Solid Biosciences Inc.NCT07160634
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedATTR Amyloidosis (Transthyretin Amyloidosis)Aug 19Alnylam PharmaceuticalsNCT07052903
Added 10 new sites: Laguna Hills, California, Chicago, Illinois, Edegem, Belgium and 7 more

Added 10 new sites: Laguna Hills, California, Chicago, Illinois, Edegem, Belgium and 7 more

sites_addedATTR Amyloidosis (Transthyretin Amyloidosis)Aug 19Alnylam PharmaceuticalsNCT07223203
Added 7 new sites: Nashville, Tennessee, Vancouver, Canada, Heidelberg, Germany and 4 more

Added 7 new sites: Nashville, Tennessee, Vancouver, Canada, Heidelberg, Germany and 4 more

eligibility_changeAdrenocortical CarcinomaAug 19Corcept TherapeuticsNCT03604198
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedAchondroplasiaAug 19Ascendis Pharma Growth Disorders A/SNCT05929807
Added 2 new sites: Paris, France, London, United Kingdom

Added 2 new sites: Paris, France, London, United Kingdom

sites_addedSpinal Muscular AtrophyAug 18BiogenNCT07221669
Added 4 new sites: Randwick, Australia, Porto Alegre, Brazil, Sai Paula, Brazil and 1 more

Added 4 new sites: Randwick, Australia, Porto Alegre, Brazil, Sai Paula, Brazil and 1 more

sites_addedSickle Cell DiseaseAug 18PfizerNCT05431088
Added 34 new sites: Mobile, Alabama, Hartford, Connecticut, Plantation, Florida and 31 more

Added 34 new sites: Mobile, Alabama, Hartford, Connecticut, Plantation, Florida and 31 more

eligibility_changeSickle Cell DiseaseAug 18PfizerNCT05431088
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedWild-Type ATTR Cardiac AmyloidosisAug 18Alnylam PharmaceuticalsNCT07052903
Added 10 new sites: Laguna Hills, California, Chicago, Illinois, Edegem, Belgium and 7 more

Added 10 new sites: Laguna Hills, California, Chicago, Illinois, Edegem, Belgium and 7 more

sites_addedWaldenström MacroglobulinemiaAug 18Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.NCT06980116
Added 8 new sites: Athens, Greece, Pátrai, Greece, Thessaloniki, Greece and 5 more

Added 8 new sites: Athens, Greece, Pátrai, Greece, Thessaloniki, Greece and 5 more

sites_addedWaldenström MacroglobulinemiaAug 18Merck Sharp & Dohme LLCNCT04728893
Added 2 new sites: Montreal, Canada, Wroclaw, Poland

Added 2 new sites: Montreal, Canada, Wroclaw, Poland

sites_addedVon Willebrand DiseaseAug 18American Thrombosis and Hemostasis NetworkNCT04398628
Added 5 new sites: Miami, Florida, Tampa, Florida, Columbus, Ohio and 2 more

Added 5 new sites: Miami, Florida, Tampa, Florida, Columbus, Ohio and 2 more

phase_changeUrea Cycle DisordersAug 18iECURE, Inc.NCT06255782
Moved from Phase 1, Phase 2 to Phase 3

Moved from Phase 1, Phase 2 to Phase 3

sites_addedThalassemiaAug 18Novo Nordisk A/SNCT06609226
Expanded from 105 to 106 sites

Expanded from 105 to 106 sites

sites_addedThalassemiaAug 18American Thrombosis and Hemostasis NetworkNCT04398628
Added 5 new sites: Miami, Florida, Tampa, Florida, Columbus, Ohio and 2 more

Added 5 new sites: Miami, Florida, Tampa, Florida, Columbus, Ohio and 2 more

sites_addedSystemic Juvenile Idiopathic ArthritisAug 18AbbVieNCT05609630
Added 1 new site: Berlin, Germany

Added 1 new site: Berlin, Germany

sites_addedSickle Cell DiseaseAug 18Novo Nordisk A/SNCT06609226
Expanded from 105 to 106 sites

Expanded from 105 to 106 sites

sites_addedSickle Cell DiseaseAug 18Novo Nordisk A/SNCT06612268
Added 2 new sites: Amsterdam, Netherlands, Al Ahsa, Saudi Arabia

Added 2 new sites: Amsterdam, Netherlands, Al Ahsa, Saudi Arabia

Enrollment UpdateSickle Cell DiseaseAug 18University of CincinnatiNCT06725550
Target enrollment increased from 10 to 120

Target enrollment increased from 10 to 120

sites_addedSickle Cell DiseaseAug 18CSL BehringNCT06699849
Added 7 new sites: Atlanta, Georgia, Chicago, Illinois, St Louis, Missouri and 4 more

Added 7 new sites: Atlanta, Georgia, Chicago, Illinois, St Louis, Missouri and 4 more

sites_addedSickle Cell DiseaseAug 18American Thrombosis and Hemostasis NetworkNCT04398628
Added 5 new sites: Miami, Florida, Tampa, Florida, Columbus, Ohio and 2 more

Added 5 new sites: Miami, Florida, Tampa, Florida, Columbus, Ohio and 2 more

sites_addedPompe DiseaseAug 17Denali Therapeutics Inc.NCT07354724
Added 1 new site: St Louis, Missouri

Added 1 new site: St Louis, Missouri

sites_addedShort Bowel SyndromeAug 17Hanmi Pharmaceutical Company LimitedNCT04775706
Added 1 new site: Skawina, Poland

Added 1 new site: Skawina, Poland

sites_addedShort Bowel SyndromeAug 17Zealand PharmaNCT07197944
Added 11 new sites: Chicago, Illinois, Leuven, Belgium, Helsinki, Finland and 8 more

Added 11 new sites: Chicago, Illinois, Leuven, Belgium, Helsinki, Finland and 8 more

Enrollment UpdateSarcoidosisAug 17Montefiore Medical CenterNCT06610019
Target enrollment increased from 5000 to 10000

Target enrollment increased from 5000 to 10000

sites_addedPulmonary Arterial HypertensionAug 17Insmed IncorporatedNCT07179380
Added 36 new sites: Gainesville, Florida, New York, New York, Cincinnati, Ohio and 33 more

Added 36 new sites: Gainesville, Florida, New York, New York, Cincinnati, Ohio and 33 more

eligibility_changePulmonary Arterial HypertensionAug 17Foresee Pharmaceuticals Co., Ltd.NCT06475781
Eligibility criteria have been updated

Eligibility criteria have been updated

Enrollment UpdatePulmonary Arterial HypertensionAug 17Bastiaan DriehuysNCT04991454
Target enrollment decreased from 60 to 20

Target enrollment decreased from 60 to 20

sites_addedPulmonary Arterial HypertensionAug 17Merck Sharp & Dohme LLCNCT07218029
Added 4 new sites: Belo Horizonte, Brazil, Lille, France, Mexico City, Mexico and 1 more

Added 4 new sites: Belo Horizonte, Brazil, Lille, France, Mexico City, Mexico and 1 more

sites_addedPulmonary Arterial HypertensionAug 17AllRock Bio, Inc.NCT07175038
Added 4 new sites: Houston, Texas, Foggia, Italy, Rome, Italy and 1 more

Added 4 new sites: Houston, Texas, Foggia, Italy, Rome, Italy and 1 more

eligibility_changePulmonary Arterial HypertensionAug 17AllRock Bio, Inc.NCT07175038
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedPrimary HyperoxaluriaAug 17Novartis PharmaceuticalsNCT07681271
Added 1 new site: Markham, Canada

Added 1 new site: Markham, Canada

Enrollment UpdatePrimary HyperoxaluriaAug 17Novartis PharmaceuticalsNCT07681271
Target enrollment increased from 80 to 100

Target enrollment increased from 80 to 100

sites_addedPrimary Biliary CholangitisAug 17Gilead SciencesNCT06051617
Added 6 new sites: New York, New York, Prague, Czechia, Villejuif, France and 3 more

Added 6 new sites: New York, New York, Prague, Czechia, Villejuif, France and 3 more

sites_addedPrader-Willi SyndromeAug 17Soleno Therapeutics, Inc.NCT07450664
Added 23 new sites: Phoenix, Arizona, Los Angeles, California, Sacramento, California and 20 more

Added 23 new sites: Phoenix, Arizona, Los Angeles, California, Sacramento, California and 20 more

eligibility_changePolycythemia VeraAug 17Chengdu Zenitar Biomedical Technology Co., LtdNCT07232290
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedPolycythemia VeraAug 17Disc Medicine, IncNCT05320198
Added 2 new sites: Los Angeles, California, Saint Albans, Australia

Added 2 new sites: Los Angeles, California, Saint Albans, Australia

Enrollment UpdatePolycythemia VeraAug 17National Cancer Institute (NCI)NCT06661915
Target enrollment increased from 62 to 78

Target enrollment increased from 62 to 78

eligibility_changePolycythemia VeraAug 17National Cancer Institute (NCI)NCT06661915
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedPolycystic Kidney DiseaseAug 17University Medical Center GroningenNCT05373264
Added 10 new sites: Antwerp, Belgium, Bordeaux, France, Lyon, France and 7 more

Added 10 new sites: Antwerp, Belgium, Bordeaux, France, Lyon, France and 7 more

eligibility_changePhenylketonuriaAug 17NGGT (Suzhou) Biotechnology Co., Ltd.NCT06687733
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedPhelan-McDermid SyndromeAug 17Neuren Pharmaceuticals LimitedNCT07281079
Added 2 new sites: Birmingham, Alabama, Ann Arbor, Michigan

Added 2 new sites: Birmingham, Alabama, Ann Arbor, Michigan

sites_addedPhelan-McDermid SyndromeAug 17Neuren Pharmaceuticals LimitedNCT07593391
Added 4 new sites: Glendale, California, Lexington, Massachusetts, Cincinnati, Ohio and 1 more

Added 4 new sites: Glendale, California, Lexington, Massachusetts, Cincinnati, Ohio and 1 more

Enrollment UpdateParoxysmal Nocturnal HemoglobinuriaAug 17AstraZenecaNCT07457151
Target enrollment increased from 8 to 27

Target enrollment increased from 8 to 27

Enrollment UpdateNTRK Fusion CancerAug 17National Cancer Institute (NCI)NCT06390852
Target enrollment decreased from 35 to 16

Target enrollment decreased from 35 to 16

sites_addedNoonan SyndromeAug 16Ascendis Pharma A/SNCT07221851
Added 2 new sites: Wilmington, Delaware, Seattle, Washington

Added 2 new sites: Wilmington, Delaware, Seattle, Washington

phase_changeNeuromyelitis OpticaAug 16Tianjin Medical University General HospitalNCT05792462
Moved from Phase 1, Phase 2 to Phase 1

Moved from Phase 1, Phase 2 to Phase 1

sites_addedNarcolepsy Type 1Aug 16Centessa Pharmaceuticals (UK) LimitedNCT07598708
Added 2 new sites: Orlando, Florida, Atlanta, Georgia

Added 2 new sites: Orlando, Florida, Atlanta, Georgia

sites_addedMyotonic DystrophyAug 16Sarepta Therapeutics, Inc.NCT06138743
Added 35 new sites: Liverpool, Australia, Birtinya, Australia, Herston, Australia and 32 more

Added 35 new sites: Liverpool, Australia, Birtinya, Australia, Herston, Australia and 32 more

eligibility_changeMyotonic DystrophyAug 16Sarepta Therapeutics, Inc.NCT06138743
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMyotonic DystrophyAug 16Virginia Commonwealth UniversityNCT06747884
Added 1 new site: Cerqueira César, Brazil

Added 1 new site: Cerqueira César, Brazil

sites_addedMyotonic DystrophyAug 16Avidity Biosciences, Inc.NCT07587242
Added 3 new sites: Madrid, Spain, Seville, Spain, Newcastle, United Kingdom

Added 3 new sites: Madrid, Spain, Seville, Spain, Newcastle, United Kingdom

sites_addedMyotonic DystrophyAug 16Dyne TherapeuticsNCT07486934
Added 8 new sites: Los Angeles, California, Edegem, Belgium, Garches, France and 5 more

Added 8 new sites: Los Angeles, California, Edegem, Belgium, Garches, France and 5 more

sites_addedMyotonic DystrophyAug 16Vertex Pharmaceuticals IncorporatedNCT06926621
Added 2 new sites: St Louis, Missouri, Richmond, Virginia

Added 2 new sites: St Louis, Missouri, Richmond, Virginia

sites_addedMyelofibrosisAug 16Disc Medicine, IncNCT05320198
Added 2 new sites: Los Angeles, California, Saint Albans, Australia

Added 2 new sites: Los Angeles, California, Saint Albans, Australia

sites_addedMyelofibrosisAug 16PharmaEssentiaNCT06468033
Added 71 new sites: Los Angeles, California, Washington D.C., District of Columbia, Kansas City, Kansas and 68 more

Added 71 new sites: Los Angeles, California, Washington D.C., District of Columbia, Kansas City, Kansas and 68 more

Enrollment UpdateMyelofibrosisAug 16National Cancer Institute (NCI)NCT06661915
Target enrollment increased from 62 to 78

Target enrollment increased from 62 to 78

eligibility_changeMyelofibrosisAug 16National Cancer Institute (NCI)NCT06661915
Eligibility criteria have been updated

Eligibility criteria have been updated

Enrollment UpdateMyelofibrosisAug 16Incyte CorporationNCT05936359
Target enrollment decreased from 225 to 160

Target enrollment decreased from 225 to 160

Enrollment UpdateMyelofibrosisAug 16Incyte CorporationNCT06313593
Target enrollment decreased from 186 to 37

Target enrollment decreased from 186 to 37

eligibility_changeMyelofibrosisAug 16Chengdu Zenitar Biomedical Technology Co., LtdNCT07317700
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMyelodysplastic SyndromesAug 16Disc Medicine, IncNCT05320198
Added 2 new sites: Los Angeles, California, Saint Albans, Australia

Added 2 new sites: Los Angeles, California, Saint Albans, Australia

Enrollment UpdateMyelodysplastic SyndromesAug 16AstraZenecaNCT07457151
Target enrollment increased from 8 to 27

Target enrollment increased from 8 to 27

sites_addedMyelodysplastic SyndromesAug 16Blueprint Medicines CorporationNCT07143669
Added 4 new sites: Evanston, Illinois, Rochester, Minnesota, Omaha, Nebraska and 1 more

Added 4 new sites: Evanston, Illinois, Rochester, Minnesota, Omaha, Nebraska and 1 more

Enrollment UpdateMyelodysplastic SyndromesAug 16Blueprint Medicines CorporationNCT07143669
Target enrollment increased from 450 to 750

Target enrollment increased from 450 to 750

eligibility_changeMyelodysplastic SyndromesAug 16Blueprint Medicines CorporationNCT07143669
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMyelodysplastic SyndromesAug 16National Cancer Institute (NCI)NCT05564390
Added 1 new site: Tampa, Florida

Added 1 new site: Tampa, Florida

Enrollment UpdateMyelodysplastic SyndromesAug 16Taiho Pharmaceutical Co., Ltd.NCT04608110
Target enrollment increased from 40 to 59

Target enrollment increased from 40 to 59

eligibility_changeMyelodysplastic SyndromesAug 16Taiho Pharmaceutical Co., Ltd.NCT04608110
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMyasthenia GravisAug 16Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyNCT06463587
Added 5 new sites: Rome, Italy, Rome, Italy, Kragujevac, Serbia and 2 more

Added 5 new sites: Rome, Italy, Rome, Italy, Kragujevac, Serbia and 2 more

Enrollment UpdateMyasthenia GravisAug 16Cabaletta BioNCT06359041
Target enrollment increased from 12 to 24

Target enrollment increased from 12 to 24

sites_addedMyasthenia GravisAug 16UCB Biopharma SRLNCT06540144
Added 2 new sites: Lodz, Poland, Yenimahalle, Turkey (Türkiye)

Added 2 new sites: Lodz, Poland, Yenimahalle, Turkey (Türkiye)

sites_addedMyasthenia GravisAug 16Kite, A Gilead CompanyNCT07304154
Added 2 new sites: Newport Beach, California, Montreal, Canada

Added 2 new sites: Newport Beach, California, Montreal, Canada

eligibility_changeMyasthenia GravisAug 16argenxNCT06298552
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_removedMyasthenia GravisAug 16Novartis PharmaceuticalsNCT06517758
Reduced from 125 to 116 sites

Reduced from 125 to 116 sites

Enrollment UpdateMyasthenia GravisAug 16CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT06688435
Target enrollment increased from 50 to 60

Target enrollment increased from 50 to 60

eligibility_changeMyasthenia GravisAug 16CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT06688435
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_removedMultiple SclerosisAug 16Novartis PharmaceuticalsNCT06869785
Reduced from 65 to 63 sites

Reduced from 65 to 63 sites

eligibility_changeMultiple SclerosisAug 16Hoffmann-La RocheNCT05704361
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMultiple SclerosisAug 16SanofiNCT07325292
Added 4 new sites: Milan, Italy, Foggia, Italy, Roma, Italy and 1 more

Added 4 new sites: Milan, Italy, Foggia, Italy, Roma, Italy and 1 more

sites_addedMultiple SclerosisAug 16Zenas BioPharma (USA), LLCNCT07299019
Added 7 new sites: Torrance, California, Choceň, Czechia, Kaunas, Lithuania and 4 more

Added 7 new sites: Torrance, California, Choceň, Czechia, Kaunas, Lithuania and 4 more

sites_addedMultiple SclerosisAug 16BiogenNCT05658497
Added 1 new site: Salford, United Kingdom

Added 1 new site: Salford, United Kingdom

sites_addedMultiple SclerosisAug 16Kite, A Gilead CompanyNCT07304154
Added 2 new sites: Newport Beach, California, Montreal, Canada

Added 2 new sites: Newport Beach, California, Montreal, Canada

sites_addedMultiple SclerosisAug 16Novartis PharmaceuticalsNCT06846281
Added 7 new sites: Hollywood, Florida, Miami, Florida, Chicago, Illinois and 4 more

Added 7 new sites: Hollywood, Florida, Miami, Florida, Chicago, Illinois and 4 more

Enrollment UpdateMultiple SclerosisAug 16Somogy Megyei Kaposi Mór Teaching HospitalNCT07411664
Target enrollment increased from 60 to 151

Target enrollment increased from 60 to 151

sites_addedMixed Connective Tissue DiseaseAug 16Milton S. Hershey Medical CenterNCT06465199
Added 2 new sites: Gainesville, Florida, Hackensack, New Jersey

Added 2 new sites: Gainesville, Florida, Hackensack, New Jersey

eligibility_changeMixed Connective Tissue DiseaseAug 16Children's National Research InstituteNCT07172958
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMesotheliomaAug 16Intergroupe Francophone de Cancerologie ThoraciqueNCT06840834
Added 1 new site: Lyon, France

Added 1 new site: Lyon, France

eligibility_changeMesotheliomaAug 16Intergroupe Francophone de Cancerologie ThoraciqueNCT06840834
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMerkel Cell CarcinomaAug 16Kupando GmbHNCT07600476
Added 1 new site: Munich, Germany

Added 1 new site: Munich, Germany

sites_removedMerkel Cell CarcinomaAug 16Marengo Therapeutics, Inc.NCT05592626
Reduced from 32 to 19 sites

Reduced from 32 to 19 sites

eligibility_changeMerkel Cell CarcinomaAug 16Marengo Therapeutics, Inc.NCT05592626
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMembranous NephropathyAug 16AstraZenecaNCT07571746
Added 1 new site: München, Germany

Added 1 new site: München, Germany

eligibility_changeMembranous NephropathyAug 16BiogenNCT06962800
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMastocytosisAug 16Blueprint Medicines CorporationNCT07143669
Added 4 new sites: Evanston, Illinois, Rochester, Minnesota, Omaha, Nebraska and 1 more

Added 4 new sites: Evanston, Illinois, Rochester, Minnesota, Omaha, Nebraska and 1 more

Enrollment UpdateMastocytosisAug 16Blueprint Medicines CorporationNCT07143669
Target enrollment increased from 450 to 750

Target enrollment increased from 450 to 750

eligibility_changeMastocytosisAug 16Blueprint Medicines CorporationNCT07143669
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedLennox-Gastaut SyndromeAug 15Longboard PharmaceuticalsNCT06908226
Added 31 new sites: Little Rock, Arkansas, San Francisco, California, Bethesda, Maryland and 28 more

Added 31 new sites: Little Rock, Arkansas, San Francisco, California, Bethesda, Maryland and 28 more

Enrollment UpdateLennox-Gastaut SyndromeAug 15Longboard PharmaceuticalsNCT06719141
Target enrollment increased from 292 to 367

Target enrollment increased from 292 to 367

sites_addedIgA NephropathyAug 15TakedaNCT06963827
Added 2 new sites: Kuala Lumpur, Malaysia, Birmingham, United Kingdom

Added 2 new sites: Kuala Lumpur, Malaysia, Birmingham, United Kingdom

sites_addedIgA NephropathyAug 15Novartis PharmaceuticalsNCT07146906
Added 3 new sites: Recife, Brazil, Natal, Brazil, Prague, Czechia

Added 3 new sites: Recife, Brazil, Natal, Brazil, Prague, Czechia

sites_removedIgA NephropathyAug 15Hoffmann-La RocheNCT05797610
Reduced from 204 to 178 sites

Reduced from 204 to 178 sites

sites_addedIdiopathic Pulmonary FibrosisAug 15Contineum TherapeuticsNCT07284459
Added 4 new sites: San Luis, Argentina, Greenslopes, Australia, Montreal, Canada and 1 more

Added 4 new sites: San Luis, Argentina, Greenslopes, Australia, Montreal, Canada and 1 more

sites_addedIdiopathic Pulmonary FibrosisAug 15Mediar TherapeuticsNCT06967805
Added 1 new site: Rotterdam, Netherlands

Added 1 new site: Rotterdam, Netherlands

sites_addedIdiopathic Pulmonary FibrosisAug 15Rein TherapeuticsNCT06968845
Added 6 new sites: Los Angeles, California, Temple, Texas, Camperdown, Australia and 3 more

Added 6 new sites: Los Angeles, California, Temple, Texas, Camperdown, Australia and 3 more

sites_addedIdiopathic Pulmonary FibrosisAug 15Avalyn Pharma Inc.NCT07194382
Added 21 new sites: Camperdown, Australia, Westmead, Australia, Vancouver, Canada and 18 more

Added 21 new sites: Camperdown, Australia, Westmead, Australia, Vancouver, Canada and 18 more

eligibility_changeIdiopathic Pulmonary FibrosisAug 15Joseph C. WuNCT05988463
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedIdiopathic Pulmonary FibrosisAug 15Duke UniversityNCT01915511
Added 3 new sites: Detroit, Michigan, Philadelphia, Pennsylvania, Colchester, Vermont

Added 3 new sites: Detroit, Michigan, Philadelphia, Pennsylvania, Colchester, Vermont

sites_addedHypoparathyroidismAug 15Amorphical Ltd.NCT06547151
Added 1 new site: Haifa, Israel

Added 1 new site: Haifa, Israel

Enrollment UpdateHypoparathyroidismAug 15Amorphical Ltd.NCT06547151
Target enrollment decreased from 81 to 62

Target enrollment decreased from 81 to 62

sites_addedHuntington DiseaseAug 15Novartis PharmaceuticalsNCT07326709
Added 13 new sites: Sacramento, California, Farmington, Connecticut, Durham, North Carolina and 10 more

Added 13 new sites: Sacramento, California, Farmington, Connecticut, Durham, North Carolina and 10 more

sites_addedHomocystinuriaAug 15Travere Therapeutics, Inc.NCT03406611
Added 5 new sites: Chicago, Illinois, New York, New York, Morrisville, North Carolina and 2 more

Added 5 new sites: Chicago, Illinois, New York, New York, Morrisville, North Carolina and 2 more

Enrollment UpdateHomocystinuriaAug 15Travere Therapeutics, Inc.NCT03406611
Target enrollment increased from 32 to 39

Target enrollment increased from 32 to 39

eligibility_changeHomocystinuriaAug 15Travere Therapeutics, Inc.NCT03406611
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeHodgkin LymphomaAug 15Wake Forest University Health SciencesNCT03505762
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedHodgkin LymphomaAug 15National Cancer Institute (NCI)NCT07332507
Added 2 new sites: Duarte, California, Pittsburgh, Pennsylvania

Added 2 new sites: Duarte, California, Pittsburgh, Pennsylvania

eligibility_changeHodgkin LymphomaAug 15Mayo ClinicNCT04996706
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedHodgkin LymphomaAug 15Merck Sharp & Dohme LLCNCT07634471
Added 1 new site: Ciudad Autonoma de Buenos Aires, Argentina

Added 1 new site: Ciudad Autonoma de Buenos Aires, Argentina

sites_addedHodgkin LymphomaAug 15Children's Oncology GroupNCT05705531
Added 4 new sites: Madera, California, Jacksonville, Florida, Orlando, Florida and 1 more

Added 4 new sites: Madera, California, Jacksonville, Florida, Orlando, Florida and 1 more

sites_removedHodgkin LymphomaAug 15BeOne MedicinesNCT05100862
Reduced from 277 to 268 sites

Reduced from 277 to 268 sites

eligibility_changeHodgkin LymphomaAug 15National Cancer Institute (NCI)NCT01676805
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeHodgkin LymphomaAug 15T. John Winhusen, PhDNCT06651177
Eligibility criteria have been updated

Eligibility criteria have been updated

Enrollment UpdateHodgkin LymphomaAug 15Divaya BhutaniNCT05346809
Target enrollment decreased from 39 to 8

Target enrollment decreased from 39 to 8

sites_addedHodgkin LymphomaAug 15AIDS Malignancy ConsortiumNCT05077527
Added 1 new site: The Bronx, New York

Added 1 new site: The Bronx, New York

sites_addedHodgkin LymphomaAug 15National Cancer Institute (NCI)NCT05675410
Added 1 new site: Sacramento, California

Added 1 new site: Sacramento, California

Enrollment UpdateHodgkin LymphomaAug 15University of BolognaNCT05725720
Target enrollment decreased from 90 to 69

Target enrollment decreased from 90 to 69

sites_addedHodgkin LymphomaAug 15University of BirminghamNCT03899337
Added 1 new site: Sutton, United Kingdom

Added 1 new site: Sutton, United Kingdom

Enrollment UpdateHodgkin LymphomaAug 15University of BirminghamNCT03899337
Target enrollment decreased from 105 to 72

Target enrollment decreased from 105 to 72

Enrollment UpdateHodgkin LymphomaAug 15AbbVieNCT06667687
Target enrollment decreased from 165 to 21

Target enrollment decreased from 165 to 21

sites_addedHodgkin LymphomaAug 15BeOne MedicinesNCT06742996
Added 4 new sites: Chicago, Illinois, Baton Rouge, Louisiana, Baltimore, Maryland and 1 more

Added 4 new sites: Chicago, Illinois, Baton Rouge, Louisiana, Baltimore, Maryland and 1 more

sites_addedGeographic AtrophyAug 14Galimedix Therapeutics IncNCT06659549
Added 7 new sites: Lyon, France, Paris, France, Tours, France and 4 more

Added 7 new sites: Lyon, France, Paris, France, Tours, France and 4 more

sites_addedHemophilia BAug 14PfizerNCT05611801
Added 32 new sites: Salt Lake City, Utah, Maruípe, Brazil, Edmonton, Canada and 29 more

Added 32 new sites: Salt Lake City, Utah, Maruípe, Brazil, Edmonton, Canada and 29 more

sites_addedHemophilia AAug 14PfizerNCT05611801
Added 32 new sites: Salt Lake City, Utah, Maruípe, Brazil, Edmonton, Canada and 29 more

Added 32 new sites: Salt Lake City, Utah, Maruípe, Brazil, Edmonton, Canada and 29 more

sites_addedGraves’ DiseaseAug 14Immunovant Sciences GmbHNCT07018323
Added 2 new sites: Thessaloniki, Greece, Torino, Italy

Added 2 new sites: Thessaloniki, Greece, Torino, Italy

sites_addedGraves’ DiseaseAug 14argenxNCT07570316
Added 4 new sites: Houston, Texas, Tbilisi, Georgia, Tbilisi, Georgia and 1 more

Added 4 new sites: Houston, Texas, Tbilisi, Georgia, Tbilisi, Georgia and 1 more

eligibility_changeGiant Cell ArteritisAug 14National Institute of Allergy and Infectious Diseases (NIAID)NCT07108387
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeGiant Cell ArteritisAug 14National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)NCT02257866
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedGeographic AtrophyAug 14Regeneron PharmaceuticalsNCT06541704
Added 1 new site: Waltham, Massachusetts

Added 1 new site: Waltham, Massachusetts

sites_removedGeographic AtrophyAug 14i-Lumen Scientific AUS PTY LTDNCT06662162
Reduced from 15 to 12 sites

Reduced from 15 to 12 sites

sites_addedGeographic AtrophyAug 14Kriya Therapeutics, Inc.NCT06765980
Added 1 new site: Erie, Pennsylvania

Added 1 new site: Erie, Pennsylvania

Enrollment UpdateGaucher DiseaseAug 14Shanghai Jiao Tong University School of MedicineNCT06528080
Target enrollment decreased from 9 to 3

Target enrollment decreased from 9 to 3

sites_addedGastrointestinal Stromal TumorAug 14Kumquat Biosciences Inc.NCT07406633
Added 1 new site: Philadelphia, Pennsylvania

Added 1 new site: Philadelphia, Pennsylvania

eligibility_changeFacioscapulohumeral Muscular DystrophyAug 14Sarepta Therapeutics, Inc.NCT06131983
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedFocal Segmental GlomerulosclerosisAug 14Akebia TherapeuticsNCT07268638
Added 2 new sites: Hialeah, Florida, Worcester, Massachusetts

Added 2 new sites: Hialeah, Florida, Worcester, Massachusetts

sites_removedFocal EpilepsyAug 14Biohaven Therapeutics Ltd.NCT06309966
Reduced from 152 to 150 sites

Reduced from 152 to 150 sites

sites_addedFocal EpilepsyAug 14Rapport Therapeutics Inc.NCT07563881
Added 3 new sites: Atlanta, Georgia, Boise, Idaho, Cleveland, Ohio

Added 3 new sites: Atlanta, Georgia, Boise, Idaho, Cleveland, Ohio

sites_removedFocal EpilepsyAug 14SK Life Science, Inc.NCT05067634
Reduced from 54 to 35 sites

Reduced from 54 to 35 sites

eligibility_changeFamilial Hypertrophic CardiomyopathyAug 14ProlaioNCT07420907
Eligibility criteria have been updated

Eligibility criteria have been updated

Enrollment UpdateFamilial Hypertrophic CardiomyopathyAug 14Montefiore Medical CenterNCT06610019
Target enrollment increased from 5000 to 10000

Target enrollment increased from 5000 to 10000

Enrollment UpdateFabry DiseaseAug 14Montefiore Medical CenterNCT06610019
Target enrollment increased from 5000 to 10000

Target enrollment increased from 5000 to 10000

Enrollment UpdateEssential ThrombocythemiaAug 14Incyte CorporationNCT05936359
Target enrollment decreased from 225 to 160

Target enrollment decreased from 225 to 160

sites_addedEssential ThrombocythemiaAug 14Disc Medicine, IncNCT05320198
Added 2 new sites: Los Angeles, California, Saint Albans, Australia

Added 2 new sites: Los Angeles, California, Saint Albans, Australia

Enrollment UpdateEssential ThrombocythemiaAug 14National Cancer Institute (NCI)NCT06661915
Target enrollment increased from 62 to 78

Target enrollment increased from 62 to 78

eligibility_changeEssential ThrombocythemiaAug 14National Cancer Institute (NCI)NCT06661915
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeEpidermolysis BullosaAug 14BioMendics, LLCNCT07027345
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedEpidermolysis BullosaAug 14Xinnate ABNCT06594393
Added 1 new site: Cincinnati, Ohio

Added 1 new site: Cincinnati, Ohio

eligibility_changeEpidermolysis BullosaAug 14Paradigm TherapeuticsNCT07482787
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedDuchenne Muscular DystrophyAug 13Solid Biosciences Inc.NCT07160634
Added 1 new site: Toronto, Canada

Added 1 new site: Toronto, Canada

eligibility_changeDuchenne Muscular DystrophyAug 13Solid Biosciences Inc.NCT07160634
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedDravet SyndromeAug 13EpygenixNCT04462770
Added 16 new sites: Buenos Aires, Argentina, Córdoba, Argentina, Córdoba, Argentina and 13 more

Added 16 new sites: Buenos Aires, Argentina, Córdoba, Argentina, Córdoba, Argentina and 13 more

eligibility_changeCushing DiseaseAug 13Corcept TherapeuticsNCT03604198
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedChronic Graft-versus-Host DiseaseAug 13Mayo ClinicNCT06729996
Added 1 new site: Pittsburgh, Pennsylvania

Added 1 new site: Pittsburgh, Pennsylvania

Enrollment UpdateChronic Graft-versus-Host DiseaseAug 13Mayo ClinicNCT06729996
Target enrollment increased from 40 to 50

Target enrollment increased from 40 to 50

eligibility_changeChronic Graft-versus-Host DiseaseAug 13Mayo ClinicNCT06729996
Eligibility criteria have been updated

Eligibility criteria have been updated

Enrollment UpdateChronic Graft-versus-Host DiseaseAug 13Massachusetts General HospitalNCT06849713
Target enrollment increased from 40 to 80

Target enrollment increased from 40 to 80

eligibility_changeChronic Graft-versus-Host DiseaseAug 13Massachusetts General HospitalNCT06849713
Eligibility criteria have been updated

Eligibility criteria have been updated

Enrollment UpdateChronic Graft-versus-Host DiseaseAug 13Unity Health TorontoNCT07301632
Target enrollment increased from 40 to 50

Target enrollment increased from 40 to 50

sites_addedChronic Graft-versus-Host DiseaseAug 13AstraZenecaNCT07446738
Added 2 new sites: Changsha, China, Kunming, China

Added 2 new sites: Changsha, China, Kunming, China

sites_addedChronic Graft-versus-Host DiseaseAug 13argenxNCT06920004
Added 7 new sites: Birmingham, Alabama, Bogotá, Colombia, Medellín, Colombia and 4 more

Added 7 new sites: Birmingham, Alabama, Bogotá, Colombia, Medellín, Colombia and 4 more

sites_addedChronic Graft-versus-Host DiseaseAug 13Novartis PharmaceuticalsNCT06858319
Added 3 new sites: Houston, Texas, Catamarca, Argentina, Toronto, Canada

Added 3 new sites: Houston, Texas, Catamarca, Argentina, Toronto, Canada

eligibility_changeChronic Graft-versus-Host DiseaseAug 13Habib KhanNCT06299514
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeChronic Graft-versus-Host DiseaseAug 13Nantes University HospitalNCT06995287
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedChronic Graft-versus-Host DiseaseAug 13Diality Inc.NCT06613568
Added 1 new site: New Hyde Park, New York

Added 1 new site: New Hyde Park, New York

sites_addedChronic Graft-versus-Host DiseaseAug 13Korea University Guro HospitalNCT07602192
Added 1 new site: Seoul, South Korea

Added 1 new site: Seoul, South Korea

eligibility_changeChronic Graft-versus-Host DiseaseAug 13Karolinska InstitutetNCT07145632
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeChronic Graft-versus-Host DiseaseAug 13Hope Biosciences LLCNCT05951777
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_removedChronic Graft-versus-Host DiseaseAug 13Uniquity One (UNI)NCT06496620
Reduced from 118 to 110 sites

Reduced from 118 to 110 sites

sites_addedChronic Graft-versus-Host DiseaseAug 13Boston Scientific CorporationNCT06827262
Added 3 new sites: Orlando, Florida, Jasper, Georgia, Houston, Texas

Added 3 new sites: Orlando, Florida, Jasper, Georgia, Houston, Texas

Enrollment UpdateChronic Graft-versus-Host DiseaseAug 13AstraZenecaNCT07221981
Target enrollment increased from 1519 to 2038

Target enrollment increased from 1519 to 2038

sites_addedChronic Graft-versus-Host DiseaseAug 13Novartis PharmaceuticalsNCT07549516
Added 26 new sites: Baden-Baden, Germany, Heidenheim, Germany, Schwäbisch Hall, Germany and 23 more

Added 26 new sites: Baden-Baden, Germany, Heidenheim, Germany, Schwäbisch Hall, Germany and 23 more

eligibility_changeChronic Graft-versus-Host DiseaseAug 13Novartis PharmaceuticalsNCT07549516
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeChronic Graft-versus-Host DiseaseAug 13AstraZenecaNCT05999877
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_removedChronic Graft-versus-Host DiseaseAug 13GenmabNCT04623541
Reduced from 83 to 81 sites

Reduced from 83 to 81 sites

Enrollment UpdateCholangiocarcinomaAug 13National Cancer Institute (NCI)NCT05211323
Target enrollment decreased from 88 to 4

Target enrollment decreased from 88 to 4

sites_addedDuchenne Muscular DystrophyAug 13Avidity Biosciences, Inc.NCT07587242
Added 3 new sites: Madrid, Spain, Seville, Spain, Newcastle, United Kingdom

Added 3 new sites: Madrid, Spain, Seville, Spain, Newcastle, United Kingdom

sites_addedDravet SyndromeAug 13Longboard PharmaceuticalsNCT06908226
Added 31 new sites: Little Rock, Arkansas, San Francisco, California, Bethesda, Maryland and 28 more

Added 31 new sites: Little Rock, Arkansas, San Francisco, California, Bethesda, Maryland and 28 more

sites_addedDravet SyndromeAug 13Longboard PharmaceuticalsNCT06660394
Added 34 new sites: Little Rock, Arkansas, San Francisco, California, Bethesda, Maryland and 31 more

Added 34 new sites: Little Rock, Arkansas, San Francisco, California, Bethesda, Maryland and 31 more

Enrollment UpdateDravet SyndromeAug 13Longboard PharmaceuticalsNCT06660394
Target enrollment decreased from 160 to 104

Target enrollment decreased from 160 to 104

eligibility_changeDilated CardiomyopathyAug 13ProlaioNCT07420907
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedDilated CardiomyopathyAug 13Nuevocor Pte. Ltd.NCT07606274
Added 2 new sites: Ann Arbor, Michigan, Columbus, Ohio

Added 2 new sites: Ann Arbor, Michigan, Columbus, Ohio

eligibility_changeDermatomyositisAug 13National Institute of Environmental Health Sciences (NIEHS)NCT07111065
Eligibility criteria have been updated

Eligibility criteria have been updated

Enrollment UpdateDermatomyositisAug 13National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)NCT00059748
Target enrollment decreased from 5000 to 756

Target enrollment decreased from 5000 to 756

sites_addedCongenital Adrenal HyperplasiaAug 13Crinetics Pharmaceuticals Inc.NCT07144163
Added 8 new sites: Aurora, Colorado, Philadelphia, Pennsylvania, Ribeirão Preto, Brazil and 5 more

Added 8 new sites: Aurora, Colorado, Philadelphia, Pennsylvania, Ribeirão Preto, Brazil and 5 more

sites_addedCongenital Adrenal HyperplasiaAug 13Crinetics Pharmaceuticals Inc.NCT07159841
Added 1 new site: Talcahuano, Chile

Added 1 new site: Talcahuano, Chile

sites_addedChronic Inflammatory Demyelinating PolyneuropathyAug 13SanofiNCT06290128
Added 3 new sites: New York, New York, São Paulo, Brazil, Lisbon, Portugal

Added 3 new sites: New York, New York, São Paulo, Brazil, Lisbon, Portugal

Enrollment UpdateChronic Inflammatory Demyelinating PolyneuropathyAug 13SanofiNCT06290128
Target enrollment decreased from 140 to 109

Target enrollment decreased from 140 to 109

eligibility_changeChronic Graft-versus-Host DiseaseAug 13ProlaioNCT07420907
Eligibility criteria have been updated

Eligibility criteria have been updated

Enrollment UpdateChronic Graft-versus-Host DiseaseAug 13Brigham and Women's HospitalNCT06722287
Target enrollment increased from 20 to 400

Target enrollment increased from 20 to 400

eligibility_changeChronic Graft-versus-Host DiseaseAug 13Brigham and Women's HospitalNCT06722287
Eligibility criteria have been updated

Eligibility criteria have been updated

Enrollment UpdateChronic Graft-versus-Host DiseaseAug 13SanofiNCT07424144
Target enrollment decreased from 380 to 59

Target enrollment decreased from 380 to 59

Enrollment UpdateChronic Graft-versus-Host DiseaseAug 13C. R. BardNCT04634916
Target enrollment decreased from 280 to 220

Target enrollment decreased from 280 to 220

Enrollment UpdateChronic Graft-versus-Host DiseaseAug 13Andreas StallmachNCT03843385
Target enrollment decreased from 129 to 84

Target enrollment decreased from 129 to 84

sites_removedChronic Graft-versus-Host DiseaseAug 13Maze TherapeuticsNCT06830629
Reduced from 81 to 79 sites

Reduced from 81 to 79 sites

Enrollment UpdateChronic Graft-versus-Host DiseaseAug 13Maze TherapeuticsNCT06830629
Target enrollment increased from 56 to 74

Target enrollment increased from 56 to 74

eligibility_changeChronic Graft-versus-Host DiseaseAug 13Maze TherapeuticsNCT06830629
Eligibility criteria have been updated

Eligibility criteria have been updated

Enrollment UpdateChronic Graft-versus-Host DiseaseAug 13AstraZenecaNCT07566195
Target enrollment decreased from 82 to 59

Target enrollment decreased from 82 to 59

sites_addedChronic Graft-versus-Host DiseaseAug 13AstraZenecaNCT03549754
Added 27 new sites: Curitiba, Brazil, Goiânia, Brazil, Bragança Paulista, Brazil and 24 more

Added 27 new sites: Curitiba, Brazil, Goiânia, Brazil, Bragança Paulista, Brazil and 24 more

sites_addedChronic Graft-versus-Host DiseaseAug 13National Cancer Institute (NCI)NCT07061951
Added 3 new sites: Columbus, Ohio, Pittsburgh, Pennsylvania, Salt Lake City, Utah

Added 3 new sites: Columbus, Ohio, Pittsburgh, Pennsylvania, Salt Lake City, Utah

sites_addedChronic Graft-versus-Host DiseaseAug 13Trevi TherapeuticsNCT07671924
Added 5 new sites: Ajax, Canada, Montreal, Canada, North Van Couver, Canada and 2 more

Added 5 new sites: Ajax, Canada, Montreal, Canada, North Van Couver, Canada and 2 more

Enrollment UpdateChronic Graft-versus-Host DiseaseAug 13Abbott Medical DevicesNCT07287423
Target enrollment increased from 20 to 30

Target enrollment increased from 20 to 30

sites_addedChronic Graft-versus-Host DiseaseAug 13Eli Lilly and CompanyNCT06672549
Added 53 new sites: Tucson, Arizona, Loma Linda, California, Los Angeles, California and 50 more

Added 53 new sites: Tucson, Arizona, Loma Linda, California, Los Angeles, California and 50 more

Enrollment UpdateChronic Graft-versus-Host DiseaseAug 13M.D. Anderson Cancer CenterNCT05007873
Target enrollment decreased from 70 to 39

Target enrollment decreased from 70 to 39

Enrollment UpdateChronic Graft-versus-Host DiseaseAug 13Necmettin Erbakan UniversityNCT07228585
Target enrollment increased from 33 to 49

Target enrollment increased from 33 to 49

Enrollment UpdateChronic Graft-versus-Host DiseaseAug 13National Cancer Institute (NCI)NCT04044365
Target enrollment decreased from 420 to 139

Target enrollment decreased from 420 to 139

sites_addedChronic Graft-versus-Host DiseaseAug 13Olympus Corporation of the AmericasNCT04302272
Added 2 new sites: Baltimore, Maryland, Houston, Texas

Added 2 new sites: Baltimore, Maryland, Houston, Texas

sites_addedChronic Graft-versus-Host DiseaseAug 13Laminate Medical TechnologiesNCT06516653
Added 2 new sites: Atlanta, Georgia, Houston, Texas

Added 2 new sites: Atlanta, Georgia, Houston, Texas

sites_addedChronic Graft-versus-Host DiseaseAug 13University of BirminghamNCT03899337
Added 1 new site: Sutton, United Kingdom

Added 1 new site: Sutton, United Kingdom

Enrollment UpdateChronic Graft-versus-Host DiseaseAug 13University of BirminghamNCT03899337
Target enrollment decreased from 105 to 72

Target enrollment decreased from 105 to 72

sites_removedChronic Graft-versus-Host DiseaseAug 13Hoffmann-La RocheNCT03523858
Reduced from 124 to 120 sites

Reduced from 124 to 120 sites

sites_addedCholangiocarcinomaAug 13Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestNCT07260175
Added 3 new sites: Hamburg, Germany, Oldenburg, Germany, Regensburg, Germany

Added 3 new sites: Hamburg, Germany, Oldenburg, Germany, Regensburg, Germany

eligibility_changeAlport SyndromeAug 12BayerNCT07211685
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedAcromegalyAug 12Camurus ABNCT07583563
Added 1 new site: Leeds, United Kingdom

Added 1 new site: Leeds, United Kingdom

sites_addedBecker Muscular DystrophyAug 12Avidity Biosciences, Inc.NCT07587242
Added 3 new sites: Madrid, Spain, Seville, Spain, Newcastle, United Kingdom

Added 3 new sites: Madrid, Spain, Seville, Spain, Newcastle, United Kingdom

sites_addedBarth SyndromeAug 12LMU KlinikumNCT05554835
Added 3 new sites: Munich, Germany, Halle, Germany, München, Germany

Added 3 new sites: Munich, Germany, Halle, Germany, München, Germany

sites_addedATTR Amyloidosis (Transthyretin Amyloidosis)Aug 12Alexion Pharmaceuticals, Inc.NCT06183931
Added 1 new site: Copenhagen, Denmark

Added 1 new site: Copenhagen, Denmark

Enrollment UpdateArrhythmogenic CardiomyopathyAug 12Montefiore Medical CenterNCT06610019
Target enrollment increased from 5000 to 10000

Target enrollment increased from 5000 to 10000

sites_addedAmyotrophic Lateral SclerosisAug 12University Hospital, LimogesNCT06147843
Added 2 new sites: Hanover, Germany, Ulm, Germany

Added 2 new sites: Hanover, Germany, Ulm, Germany

phase_changeAmyotrophic Lateral SclerosisAug 12Coya TherapeuticsNCT07161999
Moved from Phase 2 to Phase 2, Phase 3

Moved from Phase 2 to Phase 2, Phase 3

eligibility_changeAmyotrophic Lateral SclerosisAug 12Coya TherapeuticsNCT07161999
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeAmyotrophic Lateral SclerosisAug 12Johns Hopkins UniversityNCT06656702
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedAlpha-1 Antitrypsin DeficiencyAug 12Tessera Therapeutics, Inc.NCT07227207
Added 1 new site: London, United Kingdom

Added 1 new site: London, United Kingdom

sites_addedAdrenocortical CarcinomaAug 12National Cancer Institute (NCI)NCT06900595
Added 1 new site: Rochester, Minnesota

Added 1 new site: Rochester, Minnesota

sites_addedTurner SyndromeAug 11Ascendis Pharma A/SNCT07221851
Added 2 new sites: Wilmington, Delaware, Seattle, Washington

Added 2 new sites: Wilmington, Delaware, Seattle, Washington

eligibility_changeTakayasu ArteritisAug 11National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)NCT02257866
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_removedWaldenström MacroglobulinemiaAug 11BeOne MedicinesNCT05006716
Reduced from 127 to 114 sites

Reduced from 127 to 114 sites

sites_removedWaldenström MacroglobulinemiaAug 11BeiGeneNCT07169331
Reduced from 8 to 6 sites

Reduced from 8 to 6 sites

eligibility_changeThalassemiaAug 11Bristol-Myers SquibbNCT05664737
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedStargardt DiseaseAug 11Astellas Pharma Global Development, Inc.NCT07425574
Added 1 new site: Jacksonville, Florida

Added 1 new site: Jacksonville, Florida

sites_addedSpinal Muscular AtrophyAug 11argenxNCT07287982
Added 7 new sites: Cambridge, United Kingdom, London, United Kingdom, Oxford, United Kingdom and 4 more

Added 7 new sites: Cambridge, United Kingdom, London, United Kingdom, Oxford, United Kingdom and 4 more

sites_addedSickle Cell DiseaseAug 11CSL BehringNCT07224360
Added 11 new sites: Orange, California, Atlanta, Georgia, Columbus, Ohio and 8 more

Added 11 new sites: Orange, California, Atlanta, Georgia, Columbus, Ohio and 8 more

eligibility_changeSickle Cell DiseaseAug 11CSL BehringNCT07224360
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedRetinitis PigmentosaAug 10LMU KlinikumNCT05554835
Added 3 new sites: Munich, Germany, Halle, Germany, München, Germany

Added 3 new sites: Munich, Germany, Halle, Germany, München, Germany

sites_addedPulmonary Arterial HypertensionAug 10Regeneron PharmaceuticalsNCT07318597
Added 1 new site: Salamanca, Spain

Added 1 new site: Salamanca, Spain

Enrollment UpdatePulmonary Arterial HypertensionAug 10Sheffield Teaching Hospitals NHS Foundation TrustNCT05825417
Target enrollment increased from 40 to 70

Target enrollment increased from 40 to 70

eligibility_changePulmonary Arterial HypertensionAug 10Sheffield Teaching Hospitals NHS Foundation TrustNCT05825417
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedPulmonary Arterial HypertensionAug 10Tempus AINCT06911632
Added 2 new sites: Bossier City, Louisiana, Jackson, Mississippi

Added 2 new sites: Bossier City, Louisiana, Jackson, Mississippi

eligibility_changePulmonary Arterial HypertensionAug 10Tempus AINCT06911632
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedPrimary HyperoxaluriaAug 10Novartis PharmaceuticalsNCT07681271
Added 2 new sites: London, Canada, Dongjak Gu, South Korea

Added 2 new sites: London, Canada, Dongjak Gu, South Korea

sites_addedPolycythemia VeraAug 10TakedaNCT07648030
Added 5 new sites: Nagoya, Japan, Maebashi, Japan, Shinjuku-ku, Japan and 2 more

Added 5 new sites: Nagoya, Japan, Maebashi, Japan, Shinjuku-ku, Japan and 2 more

sites_addedPolycystic Kidney DiseaseAug 10Calico Life Sciences LLCNCT06902558
Added 90 new sites: Birmingham, Alabama, Huntington Park, California, Los Angeles, California and 87 more

Added 90 new sites: Birmingham, Alabama, Huntington Park, California, Los Angeles, California and 87 more

eligibility_changePhenylketonuriaAug 10The First Affiliated Hospital of Bengbu Medical UniversityNCT06061614
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedParoxysmal Nocturnal HemoglobinuriaAug 10Regeneron PharmaceuticalsNCT07154745
Added 1 new site: São Paulo, Brazil

Added 1 new site: São Paulo, Brazil

sites_addedParoxysmal Nocturnal HemoglobinuriaAug 10Hoffmann-La RocheNCT03157635
Added 1 new site: Seoul, South Korea

Added 1 new site: Seoul, South Korea

sites_addedParoxysmal Nocturnal HemoglobinuriaAug 10Novartis PharmaceuticalsNCT06934967
Added 2 new sites: Atlanta, Georgia, Cologne, Germany

Added 2 new sites: Atlanta, Georgia, Cologne, Germany

eligibility_changeNeuromyelitis OpticaAug 9Tianjin Medical University General HospitalNCT05792462
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeNeurofibromatosis Type 1Aug 9National Cancer Institute (NCI)NCT06880991
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedNarcolepsy Type 1Aug 9Alkermes, Inc.NCT07540897
Added 4 new sites: Charlotte, North Carolina, Colombia, South Carolina, Markham, Canada and 1 more

Added 4 new sites: Charlotte, North Carolina, Colombia, South Carolina, Markham, Canada and 1 more

sites_addedNarcolepsy Type 1Aug 9Alkermes, Inc.NCT07455383
Added 7 new sites: Phoenix, Arizona, Charlotte, North Carolina, Namur, Belgium and 4 more

Added 7 new sites: Phoenix, Arizona, Charlotte, North Carolina, Namur, Belgium and 4 more

sites_addedNarcolepsy Type 1Aug 9Alkermes, Inc.NCT06767683
Added 3 new sites: Cullman, Alabama, Boulder, Colorado, Kansas City, Kansas

Added 3 new sites: Cullman, Alabama, Boulder, Colorado, Kansas City, Kansas

sites_addedMyotonic DystrophyAug 9Virginia Commonwealth UniversityNCT06747884
Added 2 new sites: Little Rock, Arkansas, Kansas City, Kansas

Added 2 new sites: Little Rock, Arkansas, Kansas City, Kansas

sites_addedMyelofibrosisAug 9Sumitomo Pharma America, Inc.NCT04176198
Added 6 new sites: Fitzroy, Australia, Halle, Germany, Lübeck, Germany and 3 more

Added 6 new sites: Fitzroy, Australia, Halle, Germany, Lübeck, Germany and 3 more

sites_removedMyelofibrosisAug 9TakedaNCT07623161
Reduced from 207 to 194 sites

Reduced from 207 to 194 sites

sites_addedMyelodysplastic SyndromesAug 9Regeneron PharmaceuticalsNCT07154745
Added 1 new site: São Paulo, Brazil

Added 1 new site: São Paulo, Brazil

sites_addedMyelodysplastic SyndromesAug 9Hoffmann-La RocheNCT03157635
Added 1 new site: Seoul, South Korea

Added 1 new site: Seoul, South Korea

sites_addedMyelodysplastic SyndromesAug 9Novartis PharmaceuticalsNCT06934967
Added 2 new sites: Atlanta, Georgia, Cologne, Germany

Added 2 new sites: Atlanta, Georgia, Cologne, Germany

Enrollment UpdateMyelodysplastic SyndromesAug 9M.D. Anderson Cancer CenterNCT02392572
Target enrollment decreased from 120 to 58

Target enrollment decreased from 120 to 58

sites_addedMyasthenia GravisAug 9Aurinia Pharmaceuticals Inc.NCT07596901
Added 7 new sites: Pasadena, California, Homestead, Florida, Chicago, Illinois and 4 more

Added 7 new sites: Pasadena, California, Homestead, Florida, Chicago, Illinois and 4 more

sites_addedMyasthenia GravisAug 9Vertex Pharmaceuticals IncorporatedNCT07501702
Added 2 new sites: Mission Hills, California, Poznan, Poland

Added 2 new sites: Mission Hills, California, Poznan, Poland

sites_addedMultiple System AtrophyAug 9Teva Branded Pharmaceutical Products R&D LLCNCT07197866
Added 2 new sites: Pittsburgh, Pennsylvania, Barcelona, Spain

Added 2 new sites: Pittsburgh, Pennsylvania, Barcelona, Spain

sites_addedMultiple SclerosisAug 9PhenoNet, Inc.NCT07142291
Added 1 new site: Hradec Králové, Czechia

Added 1 new site: Hradec Králové, Czechia

sites_removedMultiple SclerosisAug 9Hoffmann-La RocheNCT07074886
Reduced from 56 to 50 sites

Reduced from 56 to 50 sites

eligibility_changeMultiple SclerosisAug 9Assistance Publique Hopitaux De MarseilleNCT03600779
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMultiple SclerosisAug 9Zenas BioPharma (USA), LLCNCT07067463
Added 5 new sites: Gdansk, Poland, Lublin, Poland, Constanța, Romania and 2 more

Added 5 new sites: Gdansk, Poland, Lublin, Poland, Constanța, Romania and 2 more

phase_changeMultiple SclerosisAug 9Coya TherapeuticsNCT07161999
Moved from Phase 2 to Phase 2, Phase 3

Moved from Phase 2 to Phase 2, Phase 3

eligibility_changeMultiple SclerosisAug 9Coya TherapeuticsNCT07161999
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeMultiple SclerosisAug 9Hospital Universitari Vall d'Hebron Research InstituteNCT07168772
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMultiple SclerosisAug 9SetPoint Medical CorporationNCT06796504
Added 3 new sites: Irvine, California, Austin, Texas, Milwaukee, Wisconsin

Added 3 new sites: Irvine, California, Austin, Texas, Milwaukee, Wisconsin

eligibility_changeMultiple SclerosisAug 9SetPoint Medical CorporationNCT06796504
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMultiple SclerosisAug 9Regeneron PharmaceuticalsNCT06351592
Added 3 new sites: Ulm, Germany, Zabrze, Poland, Warsaw, Poland

Added 3 new sites: Ulm, Germany, Zabrze, Poland, Warsaw, Poland

eligibility_changeMixed Connective Tissue DiseaseAug 9Albert Einstein College of MedicineNCT05362929
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMesotheliomaAug 9SHY TherapeuticsNCT07705334
Added 1 new site: Scottsdale, Arizona

Added 1 new site: Scottsdale, Arizona

sites_addedMesotheliomaAug 9IDEAYA BiosciencesNCT07277413
Added 1 new site: Tampa, Florida

Added 1 new site: Tampa, Florida

eligibility_changeMesotheliomaAug 9David Bartlett, MDNCT07192900
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMembranous NephropathyAug 9Vertex Pharmaceuticals IncorporatedNCT07204275
Added 3 new sites: Roseville, Missouri, New York, New York, Kawasaki-shi, Japan

Added 3 new sites: Roseville, Missouri, New York, New York, Kawasaki-shi, Japan

eligibility_changeMembranous NephropathyAug 9Nanjing Bioheng Biotech Co., Ltd.NCT07203404
Eligibility criteria have been updated

Eligibility criteria have been updated

Enrollment UpdateMedullary Thyroid CancerAug 9M.D. Anderson Cancer CenterNCT06444880
Target enrollment decreased from 40 to 15

Target enrollment decreased from 40 to 15

sites_addedMastocytosisAug 9Blueprint Medicines CorporationNCT04910685
Added 4 new sites: Cali, Colombia, Maastricht, Netherlands, Krakow, Poland and 1 more

Added 4 new sites: Cali, Colombia, Maastricht, Netherlands, Krakow, Poland and 1 more

sites_addedMastocytosisAug 9Blueprint Medicines CorporationNCT07264959
Added 2 new sites: Wheaton, Maryland, Ann Arbor, Michigan

Added 2 new sites: Wheaton, Maryland, Ann Arbor, Michigan

sites_addedIgA NephropathyAug 8Novartis PharmaceuticalsNCT07498335
Added 3 new sites: Beijing, China, Chiba, Japan, Seoul, South Korea

Added 3 new sites: Beijing, China, Chiba, Japan, Seoul, South Korea

sites_addedIgA NephropathyAug 8BiogenNCT06935357
Added 5 new sites: Woolloongabba, Australia, Heidelberg, Germany, Leipzig, Germany and 2 more

Added 5 new sites: Woolloongabba, Australia, Heidelberg, Germany, Leipzig, Germany and 2 more

sites_addedIdiopathic Pulmonary FibrosisAug 8Contineum TherapeuticsNCT07284459
Added 3 new sites: Curicó, Chile, Ñuñoa, Chile, Santiago, Chile

Added 3 new sites: Curicó, Chile, Ñuñoa, Chile, Santiago, Chile

sites_addedIdiopathic Pulmonary FibrosisAug 8Avalyn Pharma Inc.NCT06951217
Added 14 new sites: Houston, Texas, San Miguel de Tucumán, Argentina, Buenos Aires, Argentina and 11 more

Added 14 new sites: Houston, Texas, San Miguel de Tucumán, Argentina, Buenos Aires, Argentina and 11 more

eligibility_changeHypoparathyroidismAug 8Ascendis Pharma Bone Diseases A/SNCT07081997
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedHuntington DiseaseAug 8Hoffmann-La RocheNCT07246941
Added 1 new site: Montral, Canada

Added 1 new site: Montral, Canada

eligibility_changeHodgkin LymphomaAug 8Malaghan Institute of Medical ResearchNCT06486051
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeHodgkin LymphomaAug 8Iksuda Therapeutics Ltd.NCT05365659
Eligibility criteria have been updated

Eligibility criteria have been updated

Enrollment UpdateHodgkin LymphomaAug 8National Cancer Institute (NCI)NCT03922724
Target enrollment decreased from 330 to 91

Target enrollment decreased from 330 to 91

sites_addedHodgkin LymphomaAug 8Regeneron PharmaceuticalsNCT06091865
Added 8 new sites: Scottsdale, Arizona, Jacksonville, Florida, Rochester, Minnesota and 5 more

Added 8 new sites: Scottsdale, Arizona, Jacksonville, Florida, Rochester, Minnesota and 5 more

sites_removedHodgkin LymphomaAug 8Seagen, a wholly owned subsidiary of PfizerNCT04404283
Reduced from 145 to 143 sites

Reduced from 145 to 143 sites

sites_removedHodgkin LymphomaAug 8Goethe UniversityNCT02872987
Reduced from 152 to 147 sites

Reduced from 152 to 147 sites

sites_addedHodgkin LymphomaAug 8Merck Sharp & Dohme LLCNCT07634471
Added 6 new sites: Durham, North Carolina, Rosario, Argentina, Badalona, Spain and 3 more

Added 6 new sites: Durham, North Carolina, Rosario, Argentina, Badalona, Spain and 3 more

eligibility_changeHodgkin LymphomaAug 8City of Hope Medical CenterNCT03011814
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedHodgkin LymphomaAug 8Merck Sharp & Dohme LLCNCT06890884
Added 4 new sites: Haine-Saint-Paul, Belgium, Kassel, Germany, Bonn, Germany and 1 more

Added 4 new sites: Haine-Saint-Paul, Belgium, Kassel, Germany, Bonn, Germany and 1 more

sites_addedHodgkin LymphomaAug 8National Cancer Institute (NCI)NCT06649812
Added 2 new sites: Buffalo, New York, Madison, Wisconsin

Added 2 new sites: Buffalo, New York, Madison, Wisconsin

Enrollment UpdateHodgkin LymphomaAug 8UNC Lineberger Comprehensive Cancer CenterNCT03696784
Target enrollment decreased from 19 to 12

Target enrollment decreased from 19 to 12

sites_removedHodgkin LymphomaAug 8BeOne MedicinesNCT05006716
Reduced from 127 to 114 sites

Reduced from 127 to 114 sites

sites_removedHodgkin LymphomaAug 8ADC Therapeutics S.A.NCT04970901
Reduced from 42 to 40 sites

Reduced from 42 to 40 sites

Enrollment UpdateHodgkin LymphomaAug 8ADC Therapeutics S.A.NCT04970901
Target enrollment decreased from 200 to 154

Target enrollment decreased from 200 to 154

eligibility_changeHodgkin LymphomaAug 8ADC Therapeutics S.A.NCT04970901
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeHodgkin LymphomaAug 8Memorial Sloan Kettering Cancer CenterNCT03618550
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedHodgkin LymphomaAug 8Hoffmann-La RocheNCT07200375
Added 2 new sites: Nanchang, China, Ningbo, China

Added 2 new sites: Nanchang, China, Ningbo, China

sites_addedHodgkin LymphomaAug 8Alliance for Clinical Trials in OncologyNCT07215910
Added 16 new sites: Boston, Massachusetts, Grand Rapids, Michigan, Grand Rapids, Michigan and 13 more

Added 16 new sites: Boston, Massachusetts, Grand Rapids, Michigan, Grand Rapids, Michigan and 13 more

sites_addedHodgkin LymphomaAug 8Miltenyi Biomedicine GmbHNCT06116110
Added 6 new sites: Gilbert, Arizona, Chicago, Illinois, Westwood, Kansas and 3 more

Added 6 new sites: Gilbert, Arizona, Chicago, Illinois, Westwood, Kansas and 3 more

eligibility_changeHodgkin LymphomaAug 8Miltenyi Biomedicine GmbHNCT06116110
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedHereditary Hemorrhagic TelangiectasiaAug 8Diagonal Therapeutics, Inc.NCT07623525
Added 7 new sites: Camperdown, Australia, Herston, Australia, Herston, Australia and 4 more

Added 7 new sites: Camperdown, Australia, Herston, Australia, Herston, Australia and 4 more

sites_addedHereditary AngioedemaAug 8Ionis Pharmaceuticals, Inc.NCT07298447
Added 3 new sites: Baton Rouge, Louisiana, Cleveland, Ohio, Roma, Italy

Added 3 new sites: Baton Rouge, Louisiana, Cleveland, Ohio, Roma, Italy

sites_addedHemophilia BAug 7CSL BehringNCT06003387
Added 1 new site: Warsaw, Poland

Added 1 new site: Warsaw, Poland

sites_addedGraves’ DiseaseAug 7Biohaven Therapeutics Ltd.NCT07661056
Added 2 new sites: Morehead City, North Carolina, Chattanooga, Tennessee

Added 2 new sites: Morehead City, North Carolina, Chattanooga, Tennessee

sites_addedHemophilia BAug 7CSL BehringNCT07080905
Added 1 new site: Marseille, France

Added 1 new site: Marseille, France

sites_addedHemophilia BAug 7Regeneron PharmaceuticalsNCT06379789
Added 2 new sites: Houston, Texas, Melbourne, Australia

Added 2 new sites: Houston, Texas, Melbourne, Australia

sites_addedHemophilia AAug 7Hoffmann-La RocheNCT07416526
Added 17 new sites: Aurora, Colorado, Iowa City, Iowa, Bonn, Germany and 14 more

Added 17 new sites: Aurora, Colorado, Iowa City, Iowa, Bonn, Germany and 14 more

sites_addedHemophilia AAug 7Hoffmann-La RocheNCT07226206
Added 1 new site: San Francisco, California

Added 1 new site: San Francisco, California

sites_addedHemophilia AAug 7Hoffmann-La RocheNCT07416604
Added 18 new sites: Aurora, Colorado, Tampa, Florida, Leuven, Belgium and 15 more

Added 18 new sites: Aurora, Colorado, Tampa, Florida, Leuven, Belgium and 15 more

sites_addedHemophilia AAug 7Regeneron PharmaceuticalsNCT06379789
Added 2 new sites: Houston, Texas, Melbourne, Australia

Added 2 new sites: Houston, Texas, Melbourne, Australia

sites_addedGraves’ DiseaseAug 7Biohaven Therapeutics Ltd.NCT07661056
Added 4 new sites: Farmington Hills, Michigan, Dallas, Texas, San Antonio, Texas and 1 more

Added 4 new sites: Farmington Hills, Michigan, Dallas, Texas, San Antonio, Texas and 1 more

sites_addedGeographic AtrophyAug 7Regeneron PharmaceuticalsNCT07230834
Added 1 new site: Arecibo, Puerto Rico

Added 1 new site: Arecibo, Puerto Rico

sites_addedGeographic AtrophyAug 7Cellio Therapeutics IncNCT07594236
Added 2 new sites: Palo Alto, California, Sacramento, California

Added 2 new sites: Palo Alto, California, Sacramento, California

sites_addedGeographic AtrophyAug 7Complement TherapeuticsNCT07144137
Added 1 new site: Durham, North Carolina

Added 1 new site: Durham, North Carolina

sites_addedGeographic AtrophyAug 7Galimedix Therapeutics IncNCT06659549
Added 6 new sites: Bordeaux, France, Lyon, France, Saint-Cyr-sur-Loire, France and 3 more

Added 6 new sites: Bordeaux, France, Lyon, France, Saint-Cyr-sur-Loire, France and 3 more

sites_addedFocal Segmental GlomerulosclerosisAug 7Boehringer IngelheimNCT07220083
Added 9 new sites: Northridge, California, Kansas City, Kansas, Columbus, Mississippi and 6 more

Added 9 new sites: Northridge, California, Kansas City, Kansas, Columbus, Mississippi and 6 more

sites_addedFocal EpilepsyAug 7Rapport Therapeutics Inc.NCT07594119
Added 1 new site: Miami, Florida

Added 1 new site: Miami, Florida

sites_addedFocal EpilepsyAug 7Praxis Precision MedicinesNCT07287163
Added 16 new sites: Miami, Florida, Plymouth, Michigan, Hackensack, New Jersey and 13 more

Added 16 new sites: Miami, Florida, Plymouth, Michigan, Hackensack, New Jersey and 13 more

sites_addedFocal EpilepsyAug 7Rapport Therapeutics Inc.NCT07563881
Added 2 new sites: Gulf Breeze, Florida, Philadelphia, Pennsylvania

Added 2 new sites: Gulf Breeze, Florida, Philadelphia, Pennsylvania

sites_addedChronic Graft-versus-Host DiseaseAug 6Ausper Biopharma Co., Ltd.NCT07511218
Added 1 new site: Hangzhou, China

Added 1 new site: Hangzhou, China

sites_addedChronic Graft-versus-Host DiseaseAug 6Gilead SciencesNCT07096193
Added 3 new sites: Sofia, Bulgaria, Hanover, Germany, Taipei, Taiwan

Added 3 new sites: Sofia, Bulgaria, Hanover, Germany, Taipei, Taiwan

sites_addedChronic Graft-versus-Host DiseaseAug 6Aveera Medical, Inc.NCT06311773
Added 6 new sites: San Bernardino, California, Lake Success, New York, Bethlehem, Pennsylvania and 3 more

Added 6 new sites: San Bernardino, California, Lake Success, New York, Bethlehem, Pennsylvania and 3 more

sites_addedChronic Graft-versus-Host DiseaseAug 6Vifor Fresenius Medical Care Renal PharmaNCT06593392
Added 4 new sites: Chengdu, China, Guangzhou, China, Wuhan, China and 1 more

Added 4 new sites: Chengdu, China, Guangzhou, China, Wuhan, China and 1 more

sites_removedChronic Graft-versus-Host DiseaseAug 6Hannover Medical SchoolNCT05810480
Reduced from 8 to 6 sites

Reduced from 8 to 6 sites

Enrollment UpdateChronic Graft-versus-Host DiseaseAug 6Hannover Medical SchoolNCT05810480
Target enrollment increased from 200 to 400

Target enrollment increased from 200 to 400

eligibility_changeChronic Graft-versus-Host DiseaseAug 6Hannover Medical SchoolNCT05810480
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_removedChronic Graft-versus-Host DiseaseAug 6Eli Lilly and CompanyNCT07218341
Reduced from 53 to 49 sites

Reduced from 53 to 49 sites

sites_addedChronic Graft-versus-Host DiseaseAug 6Newave Pharmaceutical IncNCT07342478
Added 1 new site: Spokane, Washington

Added 1 new site: Spokane, Washington

Enrollment UpdateChronic Graft-versus-Host DiseaseAug 6Institute of Liver and Biliary Sciences, IndiaNCT06831565
Target enrollment decreased from 934 to 790

Target enrollment decreased from 934 to 790

eligibility_changeChronic Graft-versus-Host DiseaseAug 6VA Office of Research and DevelopmentNCT05563792
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedChronic Graft-versus-Host DiseaseAug 6Rise Therapeutics LLCNCT05666960
Added 1 new site: Tampa, Florida

Added 1 new site: Tampa, Florida

sites_addedEosinophilic EsophagitisAug 6Regeneron PharmaceuticalsNCT07112378
Added 1 new site: Milwaukee, Wisconsin

Added 1 new site: Milwaukee, Wisconsin

sites_addedDravet SyndromeAug 6Stoke Therapeutics, IncNCT06872125
Added 3 new sites: Beijing, China, Guangzhou, China, Wuhan, China

Added 3 new sites: Beijing, China, Guangzhou, China, Wuhan, China

sites_addedDravet SyndromeAug 6Ionis Pharmaceuticals, Inc.NCT07531745
Added 1 new site: Seattle, Washington

Added 1 new site: Seattle, Washington

sites_addedDilated CardiomyopathyAug 6Kardigan, Inc.NCT07210723
Added 22 new sites: Los Angeles, California, Stanford, California, Baltimore, Maryland and 19 more

Added 22 new sites: Los Angeles, California, Stanford, California, Baltimore, Maryland and 19 more

sites_addedDesmoplastic Small Round Cell TumorAug 6National Cancer Institute (NCI)NCT04616560
Added 1 new site: Chicago, Illinois

Added 1 new site: Chicago, Illinois

sites_addedDermatomyositisAug 6Allogene TherapeuticsNCT07085104
Added 1 new site: Kansas City, Kansas

Added 1 new site: Kansas City, Kansas

sites_addedChronic Inflammatory Demyelinating PolyneuropathyAug 6Janssen Research & Development, LLCNCT05327114
Added 1 new site: Buenos Aires, Argentina

Added 1 new site: Buenos Aires, Argentina

Enrollment UpdateChronic Granulomatous DiseaseAug 6National Institute of Allergy and Infectious Diseases (NIAID)NCT06325709
Target enrollment increased from 10 to 15

Target enrollment increased from 10 to 15

eligibility_changeChronic Granulomatous DiseaseAug 6National Institute of Allergy and Infectious Diseases (NIAID)NCT06325709
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeChronic Graft-versus-Host DiseaseAug 6Novartis PharmaceuticalsNCT04925479
Eligibility criteria have been updated

Eligibility criteria have been updated

Enrollment UpdateChronic Graft-versus-Host DiseaseAug 6Universidad Autonoma de Nuevo LeonNCT06861478
Target enrollment decreased from 80 to 60

Target enrollment decreased from 80 to 60

sites_addedChronic Graft-versus-Host DiseaseAug 6Ascendis Pharma A/SNCT07706764
Added 2 new sites: Bron, France, Le Kremlin-Bicêtre, France

Added 2 new sites: Bron, France, Le Kremlin-Bicêtre, France

sites_removedChronic Graft-versus-Host DiseaseAug 6Hoffmann-La RocheNCT04548999
Reduced from 149 to 147 sites

Reduced from 149 to 147 sites

sites_addedChronic Graft-versus-Host DiseaseAug 6IntegerBioNCT07389044
Added 2 new sites: Chisinau, Moldova, Auckland, New Zealand

Added 2 new sites: Chisinau, Moldova, Auckland, New Zealand

eligibility_changeChronic Graft-versus-Host DiseaseAug 6IntegerBioNCT07389044
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeChronic Graft-versus-Host DiseaseAug 6Weill Medical College of Cornell UniversityNCT07225049
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedChronic Graft-versus-Host DiseaseAug 6Astellas Pharma IncNCT07318714
Added 1 new site: Tokushima, Japan

Added 1 new site: Tokushima, Japan

eligibility_changeChronic Graft-versus-Host DiseaseAug 6Imam Abdulrahman Bin Faisal UniversityNCT07607314
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedChronic Graft-versus-Host DiseaseAug 6PETHEMA FoundationNCT06544785
Added 19 new sites: Alicante, Spain, Barcelona, Spain, Barcelona, Spain and 16 more

Added 19 new sites: Alicante, Spain, Barcelona, Spain, Barcelona, Spain and 16 more

Enrollment UpdateChronic Graft-versus-Host DiseaseAug 6Hoffmann-La RocheNCT05091424
Target enrollment increased from 137 to 332

Target enrollment increased from 137 to 332

eligibility_changeChronic Graft-versus-Host DiseaseAug 6Hoffmann-La RocheNCT05091424
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedChronic Graft-versus-Host DiseaseAug 6Ausper Biopharma Co., Ltd.NCT07137910
Added 11 new sites: Beijing, China, Chongqing, China, Chongqing, China and 8 more

Added 11 new sites: Beijing, China, Chongqing, China, Chongqing, China and 8 more

Enrollment UpdateChronic Graft-versus-Host DiseaseAug 6Ausper Biopharma Co., Ltd.NCT07137910
Target enrollment increased from 60 to 200

Target enrollment increased from 60 to 200

Enrollment UpdateChronic Graft-versus-Host DiseaseAug 6Saint Francis HospitalNCT06246526
Target enrollment increased from 25 to 50

Target enrollment increased from 25 to 50

eligibility_changeChronic Graft-versus-Host DiseaseAug 6Asger Lund, MDNCT05949281
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeChronic Graft-versus-Host DiseaseAug 6EPC Education s.r.o.NCT07559890
Eligibility criteria have been updated

Eligibility criteria have been updated

Enrollment UpdateCholangiocarcinomaAug 6Servier Affaires MédicalesNCT05876754
Target enrollment increased from 220 to 299

Target enrollment increased from 220 to 299

sites_addedCholangiocarcinomaAug 6Pliant Therapeutics, Inc.NCT06270706
Added 6 new sites: East Brunswick, New Jersey, Lake Success, New York, Wilson, North Carolina and 3 more

Added 6 new sites: East Brunswick, New Jersey, Lake Success, New York, Wilson, North Carolina and 3 more

sites_addedCholangiocarcinomaAug 6iOMEDICO AGNCT06607302
Added 3 new sites: Augsburg, Germany, Berlin, Germany, Passau, Germany

Added 3 new sites: Augsburg, Germany, Berlin, Germany, Passau, Germany

sites_addedAdrenocortical CarcinomaAug 5National Cancer Institute (NCI)NCT06900595
Added 1 new site: Jacksonville, Florida

Added 1 new site: Jacksonville, Florida

sites_addedC3 GlomerulopathyAug 5eleva GmbHNCT07483827
Added 1 new site: Belgrade, Serbia

Added 1 new site: Belgrade, Serbia

sites_addedATTR Amyloidosis (Transthyretin Amyloidosis)Aug 5Eidos Therapeutics, a BridgeBio companyNCT06563895
Added 1 new site: Miami, Florida

Added 1 new site: Miami, Florida

sites_addedAmyotrophic Lateral SclerosisAug 5St. Joseph's Hospital and Medical Center, PhoenixNCT06578195
Added 5 new sites: Los Angeles, California, Davie, Florida, Chicago, Illinois and 2 more

Added 5 new sites: Los Angeles, California, Davie, Florida, Chicago, Illinois and 2 more

eligibility_changeAmyotrophic Lateral SclerosisAug 5University of MinnesotaNCT06735014
Eligibility criteria have been updated

Eligibility criteria have been updated

Enrollment UpdateAmyotrophic Lateral SclerosisAug 5National Center of Neurology and Psychiatry, JapanNCT07257302
Target enrollment increased from 15 to 25

Target enrollment increased from 15 to 25

sites_addedAchondroplasiaAug 5Tyra Biosciences, IncNCT06842355
Added 2 new sites: London, United Kingdom, Sheffield, United Kingdom

Added 2 new sites: London, United Kingdom, Sheffield, United Kingdom

sites_addedSystemic MastocytosisAug 4Blueprint Medicines CorporationNCT04910685
Added 4 new sites: Cali, Colombia, Maastricht, Netherlands, Krakow, Poland and 1 more

Added 4 new sites: Cali, Colombia, Maastricht, Netherlands, Krakow, Poland and 1 more

sites_addedSystemic MastocytosisAug 4Blueprint Medicines CorporationNCT07264959
Added 2 new sites: Wheaton, Maryland, Ann Arbor, Michigan

Added 2 new sites: Wheaton, Maryland, Ann Arbor, Michigan

sites_addedStargardt DiseaseAug 4Cellio Therapeutics IncNCT07594236
Added 2 new sites: Palo Alto, California, Sacramento, California

Added 2 new sites: Palo Alto, California, Sacramento, California

sites_addedWaldenström MacroglobulinemiaAug 4National Cancer Institute (NCI)NCT04840602
Added 2 new sites: Detroit, Michigan, Farmington Hills, Michigan

Added 2 new sites: Detroit, Michigan, Farmington Hills, Michigan

sites_addedStargardt DiseaseAug 4AAVantgarde Bio SrlNCT07161544
Added 1 new site: Jacksonville, Florida

Added 1 new site: Jacksonville, Florida

sites_addedSpinal Muscular AtrophyAug 4BiogenNCT07221669
Added 2 new sites: Distrito Federal, Brazil, Guangzhou, China

Added 2 new sites: Distrito Federal, Brazil, Guangzhou, China

Enrollment UpdateSickle Cell DiseaseAug 4University of CincinnatiNCT06725550
Target enrollment decreased from 120 to 10

Target enrollment decreased from 120 to 10

Enrollment UpdateSickle Cell DiseaseAug 4Indiana UniversityNCT05045820
Target enrollment increased from 60 to 106

Target enrollment increased from 60 to 106

sites_addedSickle Cell DiseaseAug 4Disc Medicine, IncNCT07187973
Added 1 new site: Chicago, Illinois

Added 1 new site: Chicago, Illinois

Enrollment UpdateSickle Cell DiseaseAug 4Indiana UniversityNCT06511453
Target enrollment decreased from 300 to 59

Target enrollment decreased from 300 to 59

sites_addedPulmonary Arterial HypertensionAug 3Diagonal Therapeutics, Inc.NCT07623525
Added 7 new sites: Camperdown, Australia, Herston, Australia, Herston, Australia and 4 more

Added 7 new sites: Camperdown, Australia, Herston, Australia, Herston, Australia and 4 more

sites_addedProgressive Familial Intrahepatic CholestasisAug 3IpsenNCT07588880
Added 2 new sites: Nanjing, China, Xiamen, China

Added 2 new sites: Nanjing, China, Xiamen, China

sites_addedPrimary Sclerosing CholangitisAug 3IpsenNCT07387549
Added 2 new sites: Houston, Texas, Seattle, Washington

Added 2 new sites: Houston, Texas, Seattle, Washington

sites_addedPrimary Biliary CholangitisAug 3IpsenNCT07387549
Added 2 new sites: Houston, Texas, Seattle, Washington

Added 2 new sites: Houston, Texas, Seattle, Washington

sites_addedPrimary Biliary CholangitisAug 3IpsenNCT06447168
Added 6 new sites: Camperdown, Australia, Busan, South Korea, Seongnam-si, South Korea and 3 more

Added 6 new sites: Camperdown, Australia, Busan, South Korea, Seongnam-si, South Korea and 3 more

Enrollment UpdateShort Bowel SyndromeAug 3Zealand PharmaNCT07228403
Target enrollment decreased from 35 to 28

Target enrollment decreased from 35 to 28

Enrollment UpdateRetinitis PigmentosaAug 3jCyte, IncNCT06912633
Target enrollment decreased from 60 to 31

Target enrollment decreased from 60 to 31

sites_removedRetinitis PigmentosaAug 3jCyte, IncNCT06912633
Reduced from 14 to 12 sites

Reduced from 14 to 12 sites

sites_addedPulmonary Langerhans Cell HistiocytosisAug 3National Cancer Institute (NCI)NCT05828069
Added 1 new site: Green Bay, Wisconsin

Added 1 new site: Green Bay, Wisconsin

sites_addedPulmonary Arterial HypertensionAug 3Merck Sharp & Dohme LLCNCT07218029
Added 1 new site: Washington D.C., District of Columbia

Added 1 new site: Washington D.C., District of Columbia

sites_addedPulmonary Arterial HypertensionAug 3Gossamer Bio USA, Inc.NCT06274801
Added 5 new sites: Anderlecht, Belgium, Dresden, Germany, Rotterdam, Netherlands and 2 more

Added 5 new sites: Anderlecht, Belgium, Dresden, Germany, Rotterdam, Netherlands and 2 more

sites_addedProgressive Supranuclear PalsyAug 3Novartis PharmaceuticalsNCT07498426
Added 16 new sites: Scottsdale, Arizona, Westmead, Australia, Shanghai, China and 13 more

Added 16 new sites: Scottsdale, Arizona, Westmead, Australia, Shanghai, China and 13 more

sites_addedPrimary Sclerosing CholangitisAug 3Assistance Publique - Hôpitaux de ParisNCT06675604
Added 33 new sites: Brussels, Belgium, Leuven, Belgium, Leuven, Belgium and 30 more

Added 33 new sites: Brussels, Belgium, Leuven, Belgium, Leuven, Belgium and 30 more

eligibility_changePrimary Biliary CholangitisAug 3Xijing Hospital of Digestive DiseasesNCT07104201
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedPrimary Biliary CholangitisAug 3Assistance Publique - Hôpitaux de ParisNCT06675604
Added 33 new sites: Brussels, Belgium, Leuven, Belgium, Leuven, Belgium and 30 more

Added 33 new sites: Brussels, Belgium, Leuven, Belgium, Leuven, Belgium and 30 more

sites_addedPolycythemia VeraAug 3Prelude Therapeutics IncorporatedNCT07469891
Added 3 new sites: Tampa, Florida, Nashville, Tennessee, Houston, Texas

Added 3 new sites: Tampa, Florida, Nashville, Tennessee, Houston, Texas

Enrollment UpdatePolycythemia VeraAug 3Eilean Therapeutics AU Pty LtdNCT07527221
Target enrollment increased from 40 to 64

Target enrollment increased from 40 to 64

sites_addedParoxysmal Nocturnal HemoglobinuriaAug 3Regeneron PharmaceuticalsNCT05744921
Added 1 new site: Changhua, Taiwan

Added 1 new site: Changhua, Taiwan

sites_addedNoonan SyndromeAug 2Ascendis Pharma A/SNCT07221851
Added 3 new sites: Paris, France, Florence, Italy, Târgu Mureş, Romania

Added 3 new sites: Paris, France, Florence, Italy, Târgu Mureş, Romania

sites_addedNarcolepsy Type 1Aug 2Centessa Pharmaceuticals (UK) LimitedNCT07598708
Added 3 new sites: Colorado Springs, Colorado, Flowood, Mississippi, Dublin, Ohio

Added 3 new sites: Colorado Springs, Colorado, Flowood, Mississippi, Dublin, Ohio

sites_addedMyotonic DystrophyAug 2PepGen IncNCT06667453
Added 4 new sites: Pusan, South Korea, Daegu, South Korea, Seoul, South Korea and 1 more

Added 4 new sites: Pusan, South Korea, Daegu, South Korea, Seoul, South Korea and 1 more

sites_addedMyotonic DystrophyAug 2Dyne TherapeuticsNCT07486934
Added 5 new sites: Salt Lake City, Utah, Marseille, France, Bonn, Germany and 2 more

Added 5 new sites: Salt Lake City, Utah, Marseille, France, Bonn, Germany and 2 more

sites_addedMyelofibrosisAug 2Prelude Therapeutics IncorporatedNCT07469891
Added 3 new sites: Tampa, Florida, Nashville, Tennessee, Houston, Texas

Added 3 new sites: Tampa, Florida, Nashville, Tennessee, Houston, Texas

Enrollment UpdateMyelofibrosisAug 2Eilean Therapeutics AU Pty LtdNCT07527221
Target enrollment increased from 40 to 64

Target enrollment increased from 40 to 64

eligibility_changeMyelofibrosisAug 2Memorial Sloan Kettering Cancer CenterNCT06773195
Eligibility criteria have been updated

Eligibility criteria have been updated

Enrollment UpdateMyelodysplastic SyndromesAug 2Sawa Ito, MDNCT06529731
Target enrollment increased from 45 to 57

Target enrollment increased from 45 to 57

eligibility_changeMyelodysplastic SyndromesAug 2Sawa Ito, MDNCT06529731
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMyelodysplastic SyndromesAug 2Regeneron PharmaceuticalsNCT05744921
Added 1 new site: Changhua, Taiwan

Added 1 new site: Changhua, Taiwan

sites_addedMyelodysplastic SyndromesAug 2Janssen Research & Development, LLCNCT06788509
Added 3 new sites: Macquarie University, Australia, Haifa, Israel, Tel Aviv, Israel

Added 3 new sites: Macquarie University, Australia, Haifa, Israel, Tel Aviv, Israel

Enrollment UpdateMyelodysplastic SyndromesAug 2University of NebraskaNCT04898790
Target enrollment increased from 88 to 108

Target enrollment increased from 88 to 108

eligibility_changeMyelodysplastic SyndromesAug 2City of Hope Medical CenterNCT06287944
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeMyelodysplastic SyndromesAug 2National Cancer Institute (NCI)NCT03816319
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMyelodysplastic SyndromesAug 2National Cancer Institute (NCI)NCT05554406
Added 5 new sites: Oakland, California, Roseville, California, Santa Clara, California and 2 more

Added 5 new sites: Oakland, California, Roseville, California, Santa Clara, California and 2 more

eligibility_changeMyelodysplastic SyndromesAug 2National Cancer Institute (NCI)NCT05554406
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMyelodysplastic SyndromesAug 2M.D. Anderson Cancer CenterNCT06616636
Added 1 new site: Tampa, Florida

Added 1 new site: Tampa, Florida

Enrollment UpdateMyelodysplastic SyndromesAug 2Children's Oncology GroupNCT05457556
Target enrollment decreased from 435 to 66

Target enrollment decreased from 435 to 66

eligibility_changeMyelodysplastic SyndromesAug 2National Cancer Institute (NCI)NCT06577441
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMyasthenia GravisAug 2argenxNCT07294170
Added 10 new sites: Boston, Massachusetts, Chattanooga, Tennessee, Berlin, Germany and 7 more

Added 10 new sites: Boston, Massachusetts, Chattanooga, Tennessee, Berlin, Germany and 7 more

sites_addedMyasthenia GravisAug 2Cartesian TherapeuticsNCT07089121
Added 1 new site: Cincinnati, Ohio

Added 1 new site: Cincinnati, Ohio

sites_addedMyasthenia GravisAug 2Janssen Research & Development, LLCNCT07217587
Added 2 new sites: New York, New York, Cordova, Tennessee

Added 2 new sites: New York, New York, Cordova, Tennessee

sites_addedMyasthenia GravisAug 2Novartis PharmaceuticalsNCT06744920
Added 4 new sites: Boston, Massachusetts, São Paulo, Brazil, Chiba, Japan and 1 more

Added 4 new sites: Boston, Massachusetts, São Paulo, Brazil, Chiba, Japan and 1 more

eligibility_changeMyasthenia GravisAug 2Novartis PharmaceuticalsNCT06744920
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMyasthenia GravisAug 2Immunovant Sciences GmbHNCT07039916
Added 4 new sites: Houston, Texas, Caba, Argentina, Mexico City, Mexico and 1 more

Added 4 new sites: Houston, Texas, Caba, Argentina, Mexico City, Mexico and 1 more

sites_addedMyasthenia GravisAug 2argenxNCT07284420
Added 9 new sites: Boston, Massachusetts, Berlin, Germany, Athens, Greece and 6 more

Added 9 new sites: Boston, Massachusetts, Berlin, Germany, Athens, Greece and 6 more

sites_addedMultiple System AtrophyAug 2BiogenNCT07221669
Added 2 new sites: Distrito Federal, Brazil, Guangzhou, China

Added 2 new sites: Distrito Federal, Brazil, Guangzhou, China

sites_addedMultiple System AtrophyAug 2PepGen IncNCT06667453
Added 4 new sites: Pusan, South Korea, Daegu, South Korea, Seoul, South Korea and 1 more

Added 4 new sites: Pusan, South Korea, Daegu, South Korea, Seoul, South Korea and 1 more

sites_addedMultiple System AtrophyAug 2Teva Branded Pharmaceutical Products R&D LLCNCT07197866
Added 1 new site: Valencia, Spain

Added 1 new site: Valencia, Spain

sites_addedMultiple SclerosisAug 2Hoffmann-La RocheNCT05269004
Added 4 new sites: Seattle, Washington, Calgary, Canada, Saint-Herblain, France and 1 more

Added 4 new sites: Seattle, Washington, Calgary, Canada, Saint-Herblain, France and 1 more

eligibility_changeMultiple SclerosisAug 2Holland Bloorview Kids Rehabilitation HospitalNCT06081348
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedMultiple SclerosisAug 2Novartis PharmaceuticalsNCT07225504
Added 20 new sites: Dallas, Texas, CABA, Argentina, San Juan, Argentina and 17 more

Added 20 new sites: Dallas, Texas, CABA, Argentina, San Juan, Argentina and 17 more

sites_addedMultiple SclerosisAug 2Novartis PharmaceuticalsNCT05344469
Added 3 new sites: Siegen, Germany, Görlitz, Germany, Oldenburg, Germany

Added 3 new sites: Siegen, Germany, Görlitz, Germany, Oldenburg, Germany

sites_addedMultiple SclerosisAug 2AstraZenecaNCT07295847
Added 4 new sites: Berlin, Germany, Erlangen, Germany, Jena, Germany and 1 more

Added 4 new sites: Berlin, Germany, Erlangen, Germany, Jena, Germany and 1 more

sites_removedMultiple SclerosisAug 2Hoffmann-La RocheNCT04548999
Reduced from 149 to 147 sites

Reduced from 149 to 147 sites

sites_addedMultiple SclerosisAug 2Zenas BioPharma (USA), LLCNCT07067463
Added 17 new sites: Pleven, Bulgaria, Zagreb, Croatia, Tbilisi, Georgia and 14 more

Added 17 new sites: Pleven, Bulgaria, Zagreb, Croatia, Tbilisi, Georgia and 14 more

sites_addedMultiple SclerosisAug 2TG Therapeutics, Inc.NCT07503873
Added 2 new sites: Shtip, North Macedonia, Skopje, North Macedonia

Added 2 new sites: Shtip, North Macedonia, Skopje, North Macedonia

sites_addedMultiple SclerosisAug 2Zenas BioPharma (USA), LLCNCT07299019
Added 5 new sites: Naples, Florida, Nowa Sól, Poland, Rzeszów, Poland and 2 more

Added 5 new sites: Naples, Florida, Nowa Sól, Poland, Rzeszów, Poland and 2 more

sites_addedMixed Connective Tissue DiseaseAug 2National Cancer Institute (NCI)NCT04616560
Added 1 new site: Chicago, Illinois

Added 1 new site: Chicago, Illinois

sites_addedMedullary Thyroid CancerAug 2University of Southern CaliforniaNCT07259304
Added 1 new site: Houston, Texas

Added 1 new site: Houston, Texas

Enrollment UpdateMedullary Thyroid CancerAug 2University of Southern CaliforniaNCT07259304
Target enrollment decreased from 250 to 118

Target enrollment decreased from 250 to 118

eligibility_changeMedullary Thyroid CancerAug 2University of Southern CaliforniaNCT07259304
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeMastocytosisAug 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00044122
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeIgG4-Related DiseaseAug 1SanofiNCT07190196
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedIgA NephropathyAug 1Alexion Pharmaceuticals, Inc.NCT07024563
Added 1 new site: Almería, Spain

Added 1 new site: Almería, Spain

Enrollment UpdateIgA NephropathyAug 1Alexion Pharmaceuticals, Inc.NCT07024563
Target enrollment increased from 24 to 36

Target enrollment increased from 24 to 36

eligibility_changeIgA NephropathyAug 1Alexion Pharmaceuticals, Inc.NCT07024563
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedIgA NephropathyAug 1TakedaNCT06963827
Added 4 new sites: Liverpool, Australia, Clayton, Australia, Kayseri, Turkey (Türkiye) and 1 more

Added 4 new sites: Liverpool, Australia, Clayton, Australia, Kayseri, Turkey (Türkiye) and 1 more

sites_addedIgA NephropathyAug 1Novartis PharmaceuticalsNCT06797518
Added 1 new site: Kuala Lumpur, Malaysia

Added 1 new site: Kuala Lumpur, Malaysia

sites_addedIgA NephropathyAug 1ADARx Pharmaceuticals, Inc.NCT06989359
Added 5 new sites: Bergamo, Italy, Pavia, Italy, Gyeonggi-do, South Korea and 2 more

Added 5 new sites: Bergamo, Italy, Pavia, Italy, Gyeonggi-do, South Korea and 2 more

eligibility_changeIdiopathic Pulmonary FibrosisAug 1Boehringer IngelheimNCT07036523
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedIdiopathic Pulmonary FibrosisAug 1Contineum TherapeuticsNCT07284459
Added 4 new sites: Rosario, Argentina, Rosario, Argentina, San Miguel de Tucumán, Argentina and 1 more

Added 4 new sites: Rosario, Argentina, Rosario, Argentina, San Miguel de Tucumán, Argentina and 1 more

eligibility_changeIdiopathic Pulmonary FibrosisAug 1National Institute of Environmental Health Sciences (NIEHS)NCT06325696
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_removedIdiopathic Pulmonary FibrosisAug 1United TherapeuticsNCT04905693
Reduced from 194 to 192 sites

Reduced from 194 to 192 sites

sites_addedHypoparathyroidismAug 1Ascendis Pharma A/SNCT07706764
Added 2 new sites: Bron, France, Le Kremlin-Bicêtre, France

Added 2 new sites: Bron, France, Le Kremlin-Bicêtre, France

eligibility_changeHypoparathyroidismAug 1Holland Bloorview Kids Rehabilitation HospitalNCT06081348
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedHuntington DiseaseAug 1Novartis PharmaceuticalsNCT07326709
Added 10 new sites: Stanford, California, Detroit, Michigan, Chapel Hill, North Carolina and 7 more

Added 10 new sites: Stanford, California, Detroit, Michigan, Chapel Hill, North Carolina and 7 more

sites_addedHodgkin LymphomaAug 1Merck Sharp & Dohme LLCNCT07519772
Added 1 new site: Krakow, Poland

Added 1 new site: Krakow, Poland

sites_addedHodgkin LymphomaAug 1Daiichi SankyoNCT07220616
Added 1 new site: Pierre-Bénite, France

Added 1 new site: Pierre-Bénite, France

eligibility_changeHodgkin LymphomaAug 1Chinese PLA General HospitalNCT07620314
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedHodgkin LymphomaAug 1Nuvation Bio Inc.NCT05303519
Added 2 new sites: Indianapolis, Indiana, Rochester, New York

Added 2 new sites: Indianapolis, Indiana, Rochester, New York

sites_addedHodgkin LymphomaAug 1National Cancer Institute (NCI)NCT05886036
Added 2 new sites: North Miami, Florida, Pittsburgh, Pennsylvania

Added 2 new sites: North Miami, Florida, Pittsburgh, Pennsylvania

eligibility_changeHodgkin LymphomaAug 1National Cancer Institute (NCI)NCT05886036
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedHodgkin LymphomaAug 1National Cancer Institute (NCI)NCT03739814
Added 1 new site: San Juan, Puerto Rico

Added 1 new site: San Juan, Puerto Rico

sites_addedHodgkin LymphomaAug 1Compass TherapeuticsNCT06150664
Added 1 new site: Fort Wayne, Indiana

Added 1 new site: Fort Wayne, Indiana

phase_changeHodgkin LymphomaAug 1University of NebraskaNCT07292272
Moved from Phase 2 to N/A

Moved from Phase 2 to N/A

sites_addedHodgkin LymphomaAug 1AstraZenecaNCT06542250
Added 1 new site: Göttingen, Germany

Added 1 new site: Göttingen, Germany

eligibility_changeHodgkin LymphomaAug 1University of California, DavisNCT05052528
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedHodgkin LymphomaAug 1Merck Sharp & Dohme LLCNCT07570173
Added 1 new site: Rome, Italy

Added 1 new site: Rome, Italy

sites_addedHodgkin LymphomaAug 1Janssen Research & Development, LLCNCT07308132
Added 10 new sites: Lille, France, Paris, France, Pierre-Bénite, France and 7 more

Added 10 new sites: Lille, France, Paris, France, Pierre-Bénite, France and 7 more

eligibility_changeHodgkin LymphomaAug 1Janssen Research & Development, LLCNCT07308132
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedHodgkin LymphomaAug 1University of Southern CaliforniaNCT07259304
Added 1 new site: Houston, Texas

Added 1 new site: Houston, Texas

Enrollment UpdateHodgkin LymphomaAug 1University of Southern CaliforniaNCT07259304
Target enrollment decreased from 250 to 118

Target enrollment decreased from 250 to 118

eligibility_changeHodgkin LymphomaAug 1University of Southern CaliforniaNCT07259304
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedHodgkin LymphomaAug 1National Cancer Institute (NCI)NCT07069699
Added 5 new sites: Fairway, Kansas, Kansas City, Kansas, Overland Park, Kansas and 2 more

Added 5 new sites: Fairway, Kansas, Kansas City, Kansas, Overland Park, Kansas and 2 more

sites_addedHodgkin LymphomaAug 1Janssen Research & Development, LLCNCT06788509
Added 3 new sites: Macquarie University, Australia, Haifa, Israel, Tel Aviv, Israel

Added 3 new sites: Macquarie University, Australia, Haifa, Israel, Tel Aviv, Israel

eligibility_changeHodgkin LymphomaAug 1University of Colorado, DenverNCT05098613
Eligibility criteria have been updated

Eligibility criteria have been updated

eligibility_changeHodgkin LymphomaAug 1National Cancer Institute (NCI)NCT06317662
Eligibility criteria have been updated

Eligibility criteria have been updated

sites_addedHodgkin LymphomaAug 1Merck Sharp & Dohme LLCNCT06717347
Added 2 new sites: Palermo, Italy, Lublin, Poland

Added 2 new sites: Palermo, Italy, Lublin, Poland

sites_addedHodgkin LymphomaAug 1Novartis PharmaceuticalsNCT06785818
Added 1 new site: Seoul, South Korea

Added 1 new site: Seoul, South Korea

sites_addedHodgkin LymphomaAug 1Institute of Hematology & Blood Diseases Hospital, ChinaNCT06764238
Added 2 new sites: Changsha, China, Shenzhen, China

Added 2 new sites: Changsha, China, Shenzhen, China

sites_addedHodgkin LymphomaAug 1National Cancer Institute (NCI)NCT07003295
Added 3 new sites: Baltimore, Maryland, Cleveland, Ohio, Pittsburgh, Pennsylvania

Added 3 new sites: Baltimore, Maryland, Cleveland, Ohio, Pittsburgh, Pennsylvania

sites_addedHereditary AngioedemaAug 1Astria Therapeutics, Inc.NCT07204938
Added 13 new sites: Prague, Czechia, Paris, France, Ashkelon, Israel and 10 more

Added 13 new sites: Prague, Czechia, Paris, France, Ashkelon, Israel and 10 more